Research Tool Patenting and Licensing and Biomedical Innovation

John P. Walsh
University of Illinois at Chicago and Tokyo University

Ashish Arora
Carnegie Mellon University

Wesley M. Cohen
Duke University

SUMMARY

Over the last two decades changes in technology and policy have altered the landscape of drug discovery. These changes have led to concerns that the patent system may be creating difficulties for those trying to do research in biomedical fields. Using interviews and archival data, we examine the changes in patenting in recent years and how these have affected innovation in pharmaceuticals and related biotech industries.

We find that there has in fact been an increase in patents on the inputs to drug discovery (“research tools”). However, we find that drug discovery has not been substantially impeded by these changes. We also find little evidence that university research has been impeded by concerns about patents on research tools. Restrictions on the use of patented genetic diagnostics, where we see some evidence of patents interfering with university research, are an important exception. There

---

1We would like to thank the Science, Technology and Economic Policy Board of the National Academy of Sciences, and the National Science Foundation (Award No. SES-9976384) for financial support. We thank Jhoanna Conde, Wei Hong, JoAnn Lee, Nancy Maloney, and Mayumi Saegusa for research assistance. We would like to thank the following for their helpful comments on earlier drafts of this chapter: John Barton, Bill Bridges, Mildred Cho, Robert Cook-Deegan, Paul David, Rebecca Eisenberg, Akira Goto, Lewis Gruber, Janet Joy, Robert Kneller, Eric Larson, Richard Levin, Stephen Merrill, Ichiro Nakayama, Pamela Popielarz, Arti Rai, and participants in the STEP Board Conference on New Research on the Operation and Effects of the Patent System October 22, 2001, Washington, D.C. and the OECD Workshop on Genetic Inventions, Intellectual Property Rights and Licensing Practices, January 24-25, 2002, Berlin, Germany, as well as the School of Information Seminar at University of Michigan.
is, also, some evidence of delays associated with negotiating access to patented research tools, and there are areas in which patents over targets limit access and where access to foundational discoveries can be restricted. There are also cases in which research is redirected to areas with more intellectual property (IP) freedom. Still, the vast majority of respondents say that there are no cases in which valuable research projects were stopped because of IP problems relating to research inputs.

We do not observe as much breakdown or even restricted access to research tools as one might expect because firms and universities have been able to develop “working solutions” that allow their research to proceed. These working solutions combine taking licenses, inventing around patents, infringement (often informally invoking a research exemption), developing and using public tools, and challenging patents in court. In addition, changes in the institutional environment, particularly new U.S. Patent and Trademark Office (USPTO) guidelines, active intervention by the National Institutes of Health (NIH), and some shift in the courts’ views toward research tool patents, appear to have further reduced the threat of breakdown and access restrictions although the environment remains uncertain.

We conclude with a discussion of the potential social welfare effects of these changes in the industry and the adoption of these working solutions for dealing with a complex patent landscape. There are social costs associated with these changes, but there are also important benefits. Although we cannot rule out the possibility of new problems in the future, our results highlight some of the mechanisms that exist for overcoming these difficulties.

INTRODUCTION

There is widespread consensus that patents have long benefited biomedical innovation. A forty-year empirical legacy suggests that patents are more effective, for example, in protecting the commercialization and licensing of innovation in the drug industry than in any other. Patents are also widely acknowledged as providing the basis for the surge in biotechnology start-up activity witnessed over the past two decades. Heller and Eisenberg (1998) and the National Re-

---

1See Scherer et al. (1959), Levin et al. (1987), Mansfield (1986), and Cohen et al. (2000). For pharmaceuticals, there is near universal agreement among our respondents that patent rights are critical to providing the incentive to conduct R&D. Indeed, data from the Carnegie Mellon Survey of Industrial R&D (cf. Cohen et al., 2000) show that the average imitation lag for the drug industry is nearly 5 years for patented products, whereas for the rest of the manufacturing sector, the average is just over 3.5 years (p < 0.01). Moreover, recent evidence shows that the profits protected by patents constitute an important incentive for drug firms to invest in R&D (Arora et al., 2002).

2For example, in one of our interviews, a licensing director for a large pharmaceutical firm said “Patents are critical for start-up firms. Without patents, we won’t even talk to a start-up about licensing.”
The National Research Council (1997) also considers the challenges for biomedical innovation posed by the patenting of research tools and upstream discoveries more generally. In a series of case studies, the National Research Council (1997, Ch. 5) documents pervasive concern over limitations on access due to the price of intellectual property and concern over the prospect of blocking of worthwhile innovations due to IP negotiations, but no actual instances of worthwhile projects that were actually blocked.

Examples include recombinant DNA (Cohen-Boyer), polymerase chain reaction (PCR), genomics databases, microarrays, assays, transgenic mice, embryonic stem cells, or knowledge of a target, that is, any cell receptor, enzyme, or other protein that is implicated in a disease and consequently represents a promising locus for drug intervention.

The case of beta-carotene-enhanced rice (GoldenRice™) illustrates a potential anticommons/thicket problem. This innovation involves using as many as 70 pieces of IP and 15 pieces of technical property spread over 31 institutions (Kryder et al., 2000). Under such conditions, Heller, Eisenberg, and Shapiro have all suggested that acquiring the rights to practice such an innovation may be prohibitively difficult.
The argument that an anticommons may emerge to undercut innovation emphasizes factors that might frustrate private incentives to realize what should otherwise be mutually beneficial trades. Merges and Nelson (1990) and Scotchmer (1991) have argued, however, that the self-interested use of even just one patent—although lacking the encumbrances of multiple claimants characterizing an “anticommons”—may also impede innovation where a technology is cumulative (i.e., where invention proceeds largely by building on prior invention). An example of such an upstream innovation in biomedicine is the discovery that a particular receptor is important for a disease, which may make that receptor a “target” for a drug development program.\(^7\) A key concern regarding the impact of patents in such cumulative technologies is that “unless licensed easily and widely,” patents—especially broad patents—on early, foundational discoveries may limit the use of these discoveries in subsequent discovery and consequently limit the pace of innovation (Merges and Nelson, 1990).\(^8\) The revolution in molecular biology and related fields over the past two decades and coincident shifts in the policy environment have now increased the salience of this concern for biomedical research and drug innovation in particular (National Research Council, 1997). Drug discovery is now more guided by prior scientific findings than previously (Gambardella, 1995; Cockburn and Henderson, 2000; Drews, 2000), and those findings are now more likely to be patented after the 1980 passage of the Bayh-Dole Act and related legislation that simplified the patenting of federally supported research outputs that are often upstream to the development of drugs and other biomedical products.

In this chapter, we consider whether biomedical innovation has suffered because of either an anticommons or restrictions on the use of upstream discoveries in subsequent research. Notwithstanding the possibility of such impediments to biomedical innovation, there is still ample reason—and recent scholarship (Arora et al., 2002)—to suggest that patenting benefits biomedical innovation, especially

---

\(^7\)For example, a Yale-Harvard collaborative group and researchers at Merck discovered (nearly simultaneously) that the immunophilin receptor FKBP might be important for immunosuppression, making it a target for research programs at Merck, Vertex (a biotech start-up), and Harvard Medical School that all tried to find chemicals that would bind to the receptor and thus could be used as drugs to suppress immune response (Werth, 1994). Successful development in this case would depend on combining the knowledge of the existence of the target with other innovations, particularly compounds that could modify the action of the target receptor.

\(^8\)Scotchmer (1991) focuses on the related issue of the allocation of rents between the holder of a pioneer patent and those who wish to build on that prior discovery, suggesting that there is no reason to believe that markets left to themselves will set that allocation in such a way that the pace of innovation in cumulative technologies is maximized. Barton (2000), in fact, suggests that the current balance “is weighted too much in favor of the initial innovator.” Scotchmer (1991) has suggested that ex ante deals between pioneers and follow-on innovators can, however, be structured to mitigate the problem.
via its considerable impact on R&D incentives or via its role in supporting an active market for technology (Arora et al., 2001). Although any ultimate policy judgment requires a consideration of the benefits and costs of patent policy, an examination of the benefit side of this calculus is outside the scope of our current study.

In the second section of this chapter, we provide background to the anticommons and restricted access problems. The third section describes our data and methods. In the fourth section, we provide an overview of the results from our interviews and assess the extent to which we witness either “anticommons” or restricted access to intellectual property (IP) on upstream discoveries and research tools. To prefigure the key result, we find little evidence of routine breakdowns in negotiations over rights, although research tool patents are observed to impose a range of social costs and there is some restriction of access. In the fifth section of the chapter, we describe the mechanisms and strategies employed by firms and other institutions that have limited the negative effects of research tool patents on innovation. The final section discusses our findings and our conclusions.

### BACKGROUND

#### Science and Policy

Changes in the science underlying biomedical innovation, and in policies affecting what can be patented and who can patent, have combined to raise concerns over the impact of the patenting and licensing of upstream discoveries and research tools on biomedical research. Over the past twenty years, fundamental changes have revolutionized the science and technology underlying product and process innovation in drugs and the development of medical therapies and diagnostics. Advances in molecular biology have increased our understanding of the genetic bases and molecular pathways of diseases. Automated sequencing techniques and bioinformatics have greatly increased our ability to transform this understanding into patentable discoveries that can be used as targets for drug development. In addition, combinatorial chemistry and high-throughput screening techniques have dramatically increased the number of potential drugs for further development. Reflecting this increase in technological opportunity, the number of drug candidates in phase I clinical trials grew from 386 in 1990 to 1,512 in 2000.9 The consequence of these changes is that progress in biomedical research is now more cumulative; it depends more heavily than heretofore on prior scientific discoveries and previously developed research tools (Drews, 2000; Henderson et al. 1999).

---

9We thank Margaret Kyle for making these data available to us.
As the underlying science and technology has advanced, policy changes and court decisions since 1980 have expanded the range of patented subject matter and the nature of patenting institutions. In addition to the 1980 *Diamond v. Chakrabarty* decision that permitted the patenting of life-forms, and the 1988 Harvard OncoMouse patent that extended this to higher life-forms (and to a research tool), in the 1980s gene fragments, markers and a range of intermediate techniques and other inputs key to drug discovery and commercialization also became patentable. Moreover, Bayh-Dole and related legislation have encouraged universities and national labs, responsible for many such upstream developments and tools, to patent their inventions. Thus coincident changes in the science underpinning biomedicine and the policy environment surrounding IP rights have increased both the generation and patenting of upstream developments in biomedicine.

**Conceptual**

When is either an “anticommons” problem or restricted access to upstream discovery likely to emerge and why, and what are the welfare implications of their emergence?

Consider the anticommons. The central question here, as posed by both Heller and Eisenberg (1998) and Eisenberg (1999), is, if there is a cooperative surplus to be realized in combining property rights to commercialize some profitable biomedical innovation, why might it not be realized? They argue that biomedical research and innovation may be especially susceptible to breakdowns and delays in negotiations over rights for three reasons. First, the existence of numerous rights holders with claims on the inputs into the discovery process or on elements of a given product increases the likelihood that the licensing and transaction costs of bundling those rights may be greater than the ultimate value of the deal. Second, when there are different kinds of institutions holding those rights, heterogeneity in goals, norms, and managerial practice and experience can increase the difficulty and cost of reaching agreement. Such heterogeneity is manifest in biomedicine given the participation of large pharmaceutical firms, small biotechnology research firms, large chemical firms that have entered the industry (e.g., DuPont and Monsanto), and universities. Third, uncertainty over the value of rights, which is acute for upstream discoveries and research tools, can spawn asymmetric valuations that contribute to bargaining breakdowns and provide opportunities for other biases in judgment. This uncertainty is heightened because the courts have yet to interpret the validity and scope of particular patent claims.

Regarding the restriction of access to upstream discoveries highlighted by Merges and Nelson (1990; 1994), one can ask why that should be a policy concern. From a social welfare perspective, nothing is wrong with restricted access to IP for the purpose of subsequent discovery as long as the patentholder is as able as potential downstream users to fully exploit the potential contribution of
that tool or input to subsequent innovation and commercialization. This, however, is unlikely for several reasons. First, firms and, especially, universities are limited in their capabilities. Second, there is often a good deal of uncertainty about how best to build on a prior discovery, and patentholders will be limited in their views about what that prior discovery might be best used for and how to go about exploiting it. Consequently, a single patentholder is not able to exploit fully the research and commercial potential of a given upstream discovery, and society is better off to the extent that such upstream discoveries are made broadly available. For example, if there is a target receptor it is likely that there are a variety of lines of attack, and no single firm is likely capable of mounting or even conceiving of all of them. The notion that prior discoveries should be made broadly available rests, however, on an important assumption—that broad availability will not compromise the incentive to invest the effort required to come up with that discovery to begin with (cf. Scotchmer, 1991).

In this chapter, we are therefore concerned with whether the access to upstream discoveries essential to subsequent innovation is restricted. Restriction is, however, a matter of degree. If a discovery is patented at all, then it is to be expected that access will be restricted—reflecting the function of a patent. Indeed, any positive price for a license implies some degree of restriction. Therefore, we are concerned with more extreme forms of restricted access that may come in the form of exclusive licensing of broadly useful research tools, high license fees that may block classes of potential users, or decisions on the part of a patentholder to itself exploit some upstream tool or research finding that it developed.

**Historical**

The possibility that access to a key pioneering patent may be blocked, or that negotiations over patent rights might break down—even when a successful resolution would be in the collective interests of the parties concerned—is not a matter of conjecture. There is historical precedent. Merges and Nelson (1990) and Merges (1994), for example, consider the case of radio technology where the Marconi Company, De Forest, and De Forest’s main licensee, AT&T, arrived at an impasse over rights that lasted about ten years and was only resolved in 1919.

---

10That patents imply some type of output restriction due to monopoly is taken as given. The question here is whether there is any social harm if the patent holder chooses to exploit the innovation himself exclusively.

11The premise of this argument, well recognized in the economics of innovation (Jewkes et al., 1958; Evenson and Kislev, 1976; Nelson, 1982), is that, given a technological objective (e.g., curing a disease) and uncertainty about the best way to attain it, that objective will be most effectively achieved to the extent that a greater number of approaches to it are pursued.
when RCA was formed at the urging of the Navy. In aviation, Merges and Nelson argue that the refusal of the Wright brothers to license their patent significantly retarded progress in the industry. The problems caused by the initial pioneer patent (owned by the Wright brothers) were compounded as improvements and complementary patents, owned by different companies, came into existence. Ultimately, World War I forced the Secretary of the Navy to intervene to work out an automatic cross-licensing arrangement. “By the end of World War I there were so many patents on different aircraft features that a company had to negotiate a large number of licenses to produce a state-of-the-art plane.” (Merges and Nelson, 1990, p. 891)

Although breakdowns in negotiations over rights may therefore occur, rights over essential inputs to innovation are routinely transferred and cross-licensed in industries, such as the semiconductor industry, where there are numerous patents associated with a product and multiple claimants (Levin, 1982; Hall and Ziedonis, 2001; Cohen et al., 2000). In Japan, where there are many more patents per product across the entire manufacturing sector than in the United States, licensing and cross-licensing are commonplace (Cohen et al., 2002).

Thus the historical record provides instances of both where the existence of numerous rights holders and the assertion of patents on foundational discoveries have retarded commercialization and subsequent innovation and where no such retardation emerged. The history suggests several questions. Have anticommons failures occurred in biomedicine? Are they pervasive? To what degree do we observe restricted access to foundational discoveries that are essential to the subsequent advance of biomedicine? What factors might affect biomedicine’s susceptibility (or lack thereof) to either anticommons or restrictions on the use of upstream discoveries in subsequent research?

DATA AND METHOD

To address these issues, we conducted 70 interviews with IP attorneys, business managers, and scientists from 10 pharmaceutical firms and 15 biotech firms, as well as university researchers and technology transfer officers from 6 universities, patent lawyers, and government and trade association personnel. Table 1 gives the breakdown of the interview respondents by organization and occupation. These interviews averaged over one and a half hours each. The interviews focused on changes in patenting, licensing activity and the relations between pharmaceuticals, biotechnology firms, and universities, and how patent policy has affected firm behavior.

This purposive sampling was designed to solicit information from respondents representing various aspects of biomedical research and drug development (Whyte, 1984). We used the interviews to probe whether there has been a proliferation and fragmentation of patent rights and whether this has resulted in the failure to realize mutually beneficial trades, as predicted by the theory of anti-
FINDINGS

Preconditions for an Anticommons

Do conditions that might foster an “anticommons” exist in biomedicine? The essential precondition for an anticommons is the existence of multiple patents covering different components of some product, its method of manufacture, or inputs into the process through which it is discovered.

We have no direct measure of the number of patents covering a new product. There has, however, been a rapid growth in biotechnology patents over the past fifteen years, from 2,000 issued in 1985 to over 13,000 in 2000. Such rapid growth is consistent with a sizable number of patents granted for research tools and other patents related to drug development. Our interview respondents also suggest that there are indeed now more patents related to a given drug development project. One biotechnology executive responsible for IP states:

The patent landscape has gotten much more complex in the 11 years I’ve been here. I tell the story that when I started and we were interested in assessing the third party patent situation, back then, it consisted of looking at [4 or 5 named firms]. If none were working on it, that was the extent of due diligence. Now, it

TABLE 1: Distribution of Interview Respondents, by Organization and Occupation

<table>
<thead>
<tr>
<th></th>
<th>Pharmaceutical</th>
<th>Biotech</th>
<th>University</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>IP lawyer</td>
<td>12</td>
<td>7</td>
<td>—</td>
<td>12 (7)</td>
</tr>
<tr>
<td>Scientist</td>
<td>3</td>
<td>4</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>Business manager</td>
<td>9</td>
<td>7</td>
<td>3</td>
<td>—</td>
</tr>
</tbody>
</table>

NOTE: “Other” includes outside lawyers (7) and government and trade association personnel. University technology transfer office personnel are classified as “business managers,” although some are also lawyers. Also, many of the lawyers and business managers were also R&D scientists before their current position.

1http://www.bio.org/er/statistics.asp
is a routine matter that when I ask for some search for third-party patents, it is
not unusual to get an inch or two thick printout filled with patent applications
and granted patents…. In addition to dealing with patents over the end product,
there are a multitude of patents, potentially, related to intermediate research tools
that you may be concerned with as well.”

Almost half of our respondents (representing all three sectors of our sample:
big pharmaceutical firms, small biotech firms, and universities) addressed this
issue, and all of them agreed that the patent landscape has indeed become more
complex.13 How complex is, however, an important issue. Although there are
often a large number of patents potentially relevant to a given project, the actual
number needed to conduct a drug development project is often substantially
smaller. For example, Heller and Eisenberg (1998) use the case of “adrenergic
receptor” claims as an illustration of the anticommons problem and find over 100
patents that might require a license to do research in this area. Responding to the
Heller and Eisenberg article, Seide and MacLeod (1998) did a search on “adrener-
ergic receptor” and, indeed, found 135 patents using this term. They then did an
(admittedly cursory) patent clearance review and found that the vast majority
would not in fact be infringed by an assay to screen for ligands against this recep-
tor and that, at most, only a small number of licenses might be required. Another
case (from agricultural biotech) was that of putting hemoglobin in maize
(Warcoin, 2002). Here, 500 patent applications were initially reviewed, of which
100 were potentially of interest. In the end, 13 relevant patents were identified,
including research tools, specific DNA for expression, and the technology for
transforming the plant.

We asked about 10 of our industry respondents to tell us how many pieces of
IP had to be in-licensed for a typical project. They said that there may be a large
number of patents to consider initially—sometimes in the hundreds, and that this
number is surely larger than in the past. However, respondents then went on to
say that in practice there may be, in a complicated case, about 6-12 that they have
to seriously address, but that more typically the number was zero. An IP lawyer at
a biotech firm states:

The head of research comes to you and says he intends to develop this product
and he wants you to look into the patent situation. You get back an inch or two
thick pile of patents. You go through… and make judgments, what patents are
relevant? Then, you go through those more in depth…. At the next step, you are

13A few respondents noted that there is some recent backing off from mass patenting strategies. For
example, over the last few years, NIH went from patenting 90 percent of their inventions to patenting
only 40 percent (Freire, 2002). Some firms have also begun concentrating on their most promising
targets, because of the high cost of maintaining patents and the low value of many genomic patents,
particularly ESTs, that may not give rights to downstream developments in therapeutics.
left with 5-10, maybe 20, it depends. You investigate these…. In the end, there are probably 3-6 that you have to negotiate.

Thus, although most R&D executives report that the number of licenses they must obtain in the course of any given project has increased over the past decade, that number is considered to be manageable.

In addition to a larger number of patents typically bearing on a given project, the numbers and types of institutions involved have also grown. Preceding the recent growth in biotechnology patenting, the number of biotechnology firms grew rapidly in the 1980s (Cockburn et al., 2000). More recently, we observe biotechnology firms acquiring significant patent positions. Hicks et al. (2001), for example, report that the number of U.S. biotechnology firms receiving more than 50 patents in the prior six years grew from zero in 1990 to 13 by 1999.

Universities have also become major players in biotechnology, as sources of both patented biomedical inventions and start-up firms that are often founded on the strength of university-origin patents. Many respondents (14 from industry and 6 from universities) noted that this new role of universities is one of the significant changes over the last two decades in the drug and related industries. Universities have increased their patenting dramatically over the last two decades, and although still small, their share of all patents is significantly higher than before 1980. Furthermore, much of the growth in university patents tends to concentrate in a few utility classes, particularly those related to life sciences. In three of the key biomedical utility classes, universities’ share of total patents increased from about 8 percent in the early 1970s to over 25 percent by the mid-1990s (NSF, 1998). Also, universities’ adjusted gross licensing revenue has grown from 186 million dollars going to 130 universities in 1991 to 862 million dollars going to 190 universities in 1999 (AUTM, 2000), with the preponderance of these sums reflecting activity in the life sciences. An eightfold increase in university technology licensing offices from 1980 to 1995 is further evidence of increasing emphasis on the licensing of university discoveries (Mowery, et al., 2001).

Contributing to the rise in patenting, particularly in genomics, is the intensification of defensive patenting. An executive with a biotechnology firm compared its patenting strategy with that of Japanese firms in industries such as telecommunications or semiconductors: “We have a defensive patent program in genomics. It is the same as in the Japanese electronics industry. There they patent every nut and screw on a copier, camera, and build a huge portfolio, so Sony never sues Panasonic and Panasonic never sues Sony. There is a little of that going on in genomics. That way, if an IP issue ever arose, we have some cards in our hand.” A respondent from a large pharmaceutical firm made a similar comment about their motives for patenting research tools: “I supposed because we see everyone else doing it in part. Sort of like the great Oklahoma Land Rush. If you don’t do it you’re not going to have any place to set up a tent, eventually.” Overall, about a third of our industry respondents claimed to be increasing their pat-
enting of gene sequences, assays, and other research tools as a response to the patenting of others to ensure freedom to operate (see also Henry et al., 2002). Thus we observe many patents (especially on research tools) owned by different parties with different agendas. In short, the patent landscape has indeed become more complex—although not as complex as suggested by some. Nonetheless, conditions may indeed be conducive to a tragedy of the anticommons.

**Preconditions for Restricted Access to Upstream Discoveries**

Our second concern is that restrictive assertion or licensing of patents on research tools—especially foundational upstream discoveries upon which subsequent research must build (such as transgenic mice, embryonic stem cells, or knowledge of a potential drug target)—may undermine the advance of biomedical research. As suggested above, the key condition for this concern holds—namely, that research tools are now commonly patented. One R&D manager, for example, states that, “there has been a pronounced surge in patenting of research tools, previously more freely available in the public domain.” Academic scientists we interviewed affirmed this view, observing a shift from a regime in which findings were more likely to be placed in the public domain with no IP protection.

We do not have patent data on research tools and upstream discoveries per se, but a hallmark of the advance in molecular biology and related fields over the past two decades is a proliferation in new techniques and methods that are inputs into the discovery process. In addition to recombinant DNA, prominent examples include polymerase chain reaction (PCR) and Taq polymerase, OncoMouse and cre-lox technology, and countless discoveries of genes and proteins that can either be used to develop therapeutics (EPO, for example) or offer promising targets for small-molecule drugs (such as the COX-2 enzyme for pain, CCR5 receptor for HIV, or telomerase for cancer).

Restricted access to upstream technology becomes a greater concern and more limiting on downstream research activity as the claims on the upstream patents are interpreted more broadly. The complaint about Human Genome Sciences asserting its patent over the HIV receptor illustrates the concern that patent holders are able to exercise control over a broad area even when their own upstream invention is narrow and there is very little disclosed about the utility of the invention (Marshall, 2000a). At the time of the patent application, Human Genome Sciences (HGS) knew only that they had found the gene for something that was a chemokine receptor. Later work published by NIH scientists detailed how

---

14This growth in defensive patenting echoes the patent races observed in semiconductors and other complex product industries (cf. Cohen et al., 2000; Cohen et al., 2002; Hall and Ziedonis, 2001). As noted above, these other industries have for the most part managed to overcome any possible “anticommons” problem thus far.
this receptor (CCR5) worked with HIV, making this a very important drug target. Those who discovered the utility of this receptor for AIDS research and drug development filed patents, only to find that Human Genome Sciences’ “latent” discovery had priority. The concern arises is that knowledge of the reach of HGS’s patent could have deterred subsequent research on exploring the role of the gene and the associated receptor.

Another way in which the absence of a clear written description may allow upstream patents to directly affect subsequent research is via “reach-through” patent claims (as distinct from license agreements that include royalties on the product discovered using a research tool). Here, the patent claims the target and any compound that acts on the target to produce the desired effect, without describing what those compounds are. A commonly cited case is the University of Rochester’s patent on the COX-2 enzyme, which includes claims on drugs that inhibit the enzyme. This claim is the basis of the lawsuit against Searle for patent infringement. Again, if the patentholder is given broad rights to exclude others from pursuing research in this area, we could have the problem of no one in fact possessing the innovation (in this case, a COX-2 inhibitor), and greatly reduced incentives for non patent holders to explore possible uses of the innovation.

Thus there is a proliferation of patents on upstream discoveries and tools, and how those patents affect downstream discovery depends heavily on the breadth of claims. Although the USPTO has permitted broad claims to issue, there remains the question of how the courts will evaluate those claims.

Evidence of an Anticommons in Biomedical Research

Given that the preconditions for an anticommons seem to exist, we turn to our findings on the incidence and nature of the different impediments to biomedical research that an anticommons may pose. These include breakdowns in negotiations over rights, royalty stacking, and “excessive” license fees.

15USP 6,048,850: “A method for selectively inhibiting PGHS-2 activity in a human host, comprising administering a non-steroid compound that selectively inhibits activity of the PGHS-2 gene product to a human host in need of such treatment.” The compounds claimed include (but are not limited to): “nucleic acid encoding PGHS-2 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules; and pharmaceutical formulations and routes of administration for such compounds.”

16Recently, the U.S. District Court for Western New York dismissed the University of Rochester’s complaint, reasoning that the description of the discovery in the school’s patent lacked the clarity necessary to support an infringement claim [University of Rochester v. G.D. Searle & Co., Inc., No. 00-CV-6161L, 2003 WL 759719 (W.D.N.Y. Mar. 5, 2003)]. The University of Rochester indicated an intention to appeal the case. See http://www.urmc.rochester.edu/pr/news/news.cfm?id=198
Breakdowns

Perhaps the most extreme expression of an anticommons tragedy is the existence of multiple rights holders spawning a breakdown in negotiations over rights that lead to an R&D project’s cessation. We find almost no evidence of such breakdowns. Although idiosyncratic (because of the role played by policymakers and the absence of clear commercial value), the case of beta-carotene-enhanced rice (GoldenRice™) shows that the holding of IP by numerous parties need not defeat the development and commercialization of an innovation. Indeed, the complexity of this case is quite extreme, involving as many as 70 pieces of IP and 15 pieces of technical property spread over 31 institutions (Kryder et al., 2000). Although there was strong interest in this product from international aid agencies, they required general IP clearance before the product could be developed. After about a year of negotiations, Monsanto, Zeneca, and others agreed to provide royalty-free licenses for the development and distribution of this innovation in third world countries.

Beyond the case of GoldenRice™, we asked respondents and searched the literature to identify cases in which projects were stopped because of an inability to obtain access to all the necessary intellectual property rights. In brief, respondents reported that negotiations over access to necessary IP from many rights holders rarely led to a project’s cessation. Of the 55 respondents who addressed this issue (representing all three sectors), 54 could not point to a specific project stopped because of difficulties in getting agreement from multiple IP owners (the anticommons problem). For example, one respondent indicated that about a quarter of his firm’s projects were terminated in the past year. Of these, none were terminated because of any difficulties with the in-licensing of tools. Instead, the key factors included pessimism about technical success and the size of the prospective market. One biotechnology executive stated: “I am hard pressed to think of a piece of research that we haven’t done because of blocked access to a research tool. We have dropped products because others were ahead in proprietary position, but that is different.”

However, detailed study of the proprietary landscape noted that, depending on the country and the technologies that are used, the number of patents in fact could vary from 40 (in the United States or Europe) to zero (in, for example, Thailand, Bangladesh, Myanmar, Malaysia, Iran, Iraq, Saudi Arabia, or Nigeria).

Another example of a potential anticommons problem was the hepatitis B vaccine, which involved 14 pieces of IP across several organizations and produced a royalty stacking that totaled $1.47 per dose, or about 13-15 percent of sales (Hackett and Totten, 1995).

Numerous respondents reported that they did not initiate or had dropped projects if they learned another firm had already acquired a proprietary position on a drug they were considering developing—that is, on the output of a drug discovery and testing process. But that is quite different from other firms having IP for the research tools—the inputs into the discovery process.
A particular concern raised by Heller and Eisenberg (1998) and the National Research Council (1997, Ch. 5) was the prospect that, by potentially increasing the number of patent rights corresponding to a single gene, patents on expressed sequence tags (ESTs) would proliferate the number of claimants to prospective drugs and increase the likelihood of bargaining breakdowns. Our respondents suggested that this has not occurred. The key concern was that patents on the partial sequence might give the patentholder rights to the whole gene or the associated protein, or at least that the patent might block later patents issued on the gene or the protein [as Doll (1998) of the USPTO suggested]. Our respondents from industry and from the USPTO reflected, however, the view of Genentech’s Dennis Henner who testified before Congress that EST patents do not dominate the full gene sequence patent, the protein, or the protein’s use; these are separate inventions.20 Also, although the existence of large numbers of EST patents may have had the potential to create anticommons problems, the new utility and written description guidelines implemented by the USPTO will now likely prevent many EST patents from issuing and will grant those that do issue only a narrow scope of claims. In addition, it is likely that already-issued EST patents will be narrowly construed by the courts. Thus the consensus is that the storm over ESTs has largely passed.

Royalty Stacking

Another way in which multiple claimants on research tool IP may block drug discovery and development is the stacking of license fees and royalties to the point of overwhelming the commercial value of a prospective product. Most of our respondents reported that royalty stacking did not represent a significant or pervasive threat to ongoing R&D projects. One respondent said that, although stacking is a consideration, “I can’t think of any example where someone said they did not develop a therapeutic because the royalty was not reasonable.” We only heard of one instance in which a project was stopped because of royalty stacking. We were told, however, that, in this case, there were too many claimants to royalty percentages because of carelessness by a manager, who had given away royalty percentages without carefully accounting for prior agreements.21 One of our other biotechnology respondents suggested, however, that “the royalty burden can become onerous” and that the stacking of royalties “comes up pretty regularly now” with the proliferation of IP. Even here, the respondent said that no projects had ever been stopped because of royalty stacking. Overall, about

21We also had one respondent, an IP lawyer, who said such cases where projects were stopped existed, but client privilege prevented the respondent from giving details.
half of our respondents complained about licensing costs for research tools, although nearly all of those concerned about licensing costs also went on to say that the research always went forward.

Royalty stacking does not represent a significant threat to ongoing R&D projects for several reasons. First, and principally, the total of fees paid, as discussed below, typically does not push projects into a loss. Second, in the minority of cases in which the stacking of fees threatens a loss, compromises tend to be struck, often in the form of royalty offsets across the various IP holders. One respondent stated, “All are sensitive and aware of the stacking phenomenon so there is a basis for negotiation, so that you don’t have excessive royalties.” Finally, in the few cases in which such a problem might emerge, it also tends to be anticipated.

Licensing Fees for Research Tools

Although obtaining systematic data on the cost of patented research tools is difficult, half of our respondents provided enough information to allow us to approximate the range of such costs. The norm for total royalty payments for the various input technologies associated with a given drug development program is in the range of 1 to 5 percent of sales, and somewhat higher for exclusive licenses. Occasionally, royalty demands were 10 percent or higher, and these were described in such terms as “high” or “ridiculous.” Firms (especially the large pharmaceutical firms) also license particular technologies—such as using a gene for screening or a vector or microarrays—for a fee ranging from $10,000 to $200,000. These fees (especially for genes) were often described (by both those buying and those selling such technologies) as small amounts that large pharmaceutical firms paid as insurance both to ensure freedom to operate and to avoid the cost of litigation. The cost of patented reagents could be two to four times as much as do-it-yourself versions (or, in the case of Taq polymerase, buying from an unlicensed vendor), although the overall cost to the project is generally small (at most a few percent).

Large pharmaceutical firms have also been licensing access to genomic databases, and these database fees are often tens of millions of dollars and occasionally over $100 million (Science, 1997). In 1997, for access to its database, Incyte

---

22In response to a question of whether their firm ever had a case of a project being stopped for problems with royalty stacking, a biotechnology respondent stated: “No. It would be hard to find such a case, given the reality of how decisions are made. It is not a late stage decision.”
was reported to be charging $10 million to Upjohn and almost $16 million to Pfizer, as well as undisclosed amounts to eight other firms. These deals also include “low single-digit” royalties for use of patented genes in drug development. Four pharmaceutical firms paid between $44 million and $90 million each to Millennium to access their data and research tools for identifying disease genes. In 1998, Bayer agreed to a deal in which they would pay up to $465 million to Millennium to have Millennium identify 225 new drug targets within 5 years (Malakoff and Service, 2001).

Overall, our respondents noted that, although these costs were higher than before the surge in research tool patents, they believed them to be within reason largely because the productivity gains conferred by the licensed research tools were thought to be worth the price. The case of Human Genome Sciences’ database is illustrative. In 1993, SmithKline signed a deal for exclusive access for $125 million. By 1996, the database had already “saturated SmithKline with [drug-target] opportunities,” according to Human Genome Sciences’ Haseltine. Therefore, the partners extended access to the database to three other firms, who contributed a total of $140 million (Cohen, 1997a). One scientist at a large pharmaceutical firm characterized the return to paying for access to Incyte’s database as follows:

The richness in Incyte’s database is quite impressive. If you are just stuck with the things in the public database, the map is interesting, it is exciting, but it is a lot harder…. I was telling my family recently that I probably could have done my 4 year 8 month Ph.D. in about 6 months with today’s technology…. it is that big of a technology revolution.23

Thus, although the development and patenting of research tools and upstream discoveries are imposing costs on downstream users, some of those users believe that their research is substantially more productive as a consequence.

Our interviews suggested, however, that although these costs were seen as manageable by large pharmaceutical firms, and even by established biotech

---

23Randall Scott of Incyte offered several revealing examples of the productivity benefits of genomics that accord with the comments of our other respondents:

“An Incyte customer stated that it had reduced the time associated with target discovery and validation from 36 months to 18 months, through use of Incyte’s genomic information database. Other Incyte customers have privately reported similar experiences…. One Incyte customer stated that by using Incyte’s database, it quickly discovered a new histamine receptor gene which had long eluded researchers, and which is being used to develop an effective drug that is specific for brain tissue. In fact, after isolating the gene and using high-throughput screening, a candidate drug was identified in less than a month. Again, by making new targets available to the pharmaceutical industry, Incyte helped the company go from picking a target receptor to developing a potential drug in just 18 months, a process that typically takes five years or more, clearly accelerating the drug discovery process by three-fold or more” (Scott, 2000).
firms, small start-up firms and university labs noted that such costs could be prohibitive, in effect making it impossible for them to license particular research tools. This issue of restricted access due to high prices was prominently raised in the National Academy’s workshop on IP and biomedical innovation (National Research Council, 1997). One of our respondents suggested that, for example, “DNA chips are a high-investment technology. Very small labs can’t afford to do it. When the technology is out of reach of small labs, they have to collaborate. But this collaboration generally means giving up IP rights. The technology forces collaboration because barriers to entry are high.” This sentiment was echoed by university researchers we talked with. This was one justification for the “do-it-yourself” solution of making patented laboratory technology without paying royalties (Marshall, 1999b).24 Similarly, the manager of a small biotech start-up told us that Incyte’s licensing terms for access to their gene database was several times the firm’s whole annual budget. They were forced to rely on the public databases, a viable but second-best solution. One solution for universities has been the development of core facilities to share expensive resources such as chip-making facilities or high-throughput screening.

Some firms (particularly genomics firms) holding rights over research tools did, however, offer discounted terms for university and government researchers. Celera, for example, licenses their database to firms for about $5 million to $15 million per year and to university labs for about $7,500 to $15,000 (Service, 2001). In 2000, Incyte began allowing single-gene searches of its database for free, with a charge of $3,000 or more for ordering sequences or physical clones, making its database more accessible to small users (Science, 2000). Myriad also offers a discount rate (less than half the market rate) for academics doing NIH-funded research on breast cancer (Blanton, 2002).

In this section, we have considered the costs of licensing research tool IP—but only the out-of-pocket, monetary costs. Costs can, however, also take non-monetary forms. The most prominent of these for university researchers are publication restrictions, which we did not examine.25

24Affymetrix has recently adopted an easy access plan for universities to try to shift them away from a do-it-yourself approach. Several have suggested that the ability to get others to license your patented technology depends on embedding it in a form that is more convenient, reliable, or inexpensive than do-it-yourself versions would be.

25We could not obtain systematic data on the license terms for research tool technologies. However, Thursby and Thursby (1999) report that 44 percent of agreements to license university technologies to firms include publication delay clauses, with the average delay specified being almost 4 months. Also, Blumenthal et al. (1997) report that 20 percent of academic biomedical researchers have delayed research publication by 6 months or more, in part because of concerns about patents and commercialization. Thus a substantial fraction of university-industry agreements about the outputs of university research include delays of publication. We do not know whether these examples generalize to the case of agreements over the inputs to university research.
Projects Not Undertaken and Broader Determinants of R&D

Although the number of ongoing R&D projects stopped because of an anticommons problem is small, it is possible that firms avoid stacking and other difficulties in accessing IP rights by simply not undertaking a project to begin with. As a practical matter, it is difficult to measure the extent to which projects were not started or redirected because of patent-related concerns. In brief, although redirecting projects to invent around research tool patents was common, it was relatively rare for firms to move to a new research area (perhaps a new disease, or even a very different way of approaching a disease) because of concerns over one or more research tool patents. Of the eleven industry respondents who did mention IP as a cause for redirecting their research, seven, however, were primarily concerned with IP on compounds, not on research tools. An IP attorney with a large biotech firm suggested that patents on research tools were rarely determinative, reporting that in the “scores of projects” that his firm considered undertaking over the years, he could remember only one where such patent rights dissuaded them from undertaking the project. Another biotech firm’s lawyer, while reporting that they had never stopped an ongoing project because of license stacking, stated that considerations of patents on both compounds and research tools did preempt projects:

We start very early on… to assess the patent situation. When the patent situation looks too formidable, the project never gets off the ground…. Once you are well into development, you get patent issues, but not the show stopper that you would identify early on.

Although we have no systematic data on projects never pursued, our findings on the absence of breakdowns is consistent with the notion that there are relatively few cases where otherwise commercially promising projects are not undertaken because of IP on research tools. Consider Heller’s (1998) original article on the anticommons, which paints a vivid image of empty buildings in Moscow, unrented because the various owners and claim holders that could “veto” a rental arrangement were many and had trouble coming to agreement. Our analogue to an “empty building” is, of course, an R&D project that is stopped midway. However, if the argument that the proliferation of IP is generating an “anticommons” is correct, it follows that the rational anticipation of such difficulties would prevent the construction of some (or many) buildings. Likewise, some R&D projects may not be undertaken if firms anticipate difficulty in negotiating cost-effective access to the required IP. However, absent any visible empty buildings (i.e., ob-

---

26And a large number (about a third of industry respondents) said that when faced with rival patents on research tools, or even compounds, they were likely to go ahead with the research, so long as they were able to develop their own IP that would protect their compounds (see below).
served stopped projects), it is unlikely that the anticipation of breakdowns in negotiations or an excessive accumulation of claims (i.e., license stacking) prevented construction (i.e., undertaking the R&D project).

Our interviews suggested that the main reasons why projects were not undertaken reflected considerations of technological opportunity, demand, and internal resource constraints, with expected licensing fees or “tangles” of rights on tools playing a subordinate role, salient only for those projects which were commercially less viable. One industrial respondent affirmed that, although other considerations were key, royalty stacking could affect decisions at the margin: “I don’t want to say a worthwhile therapeutic was not developed because of stacking problems. But if we have two equally viable candidates, then we choose based on royalties.” One biotechnology respondent was explicit, however, about the greater importance of expected demand and technological opportunity: “At the preclinical stage, you find you have 10 candidates, and you can afford to continue work on 3. The decision is a complex prediction based on the potential for technical success, the cost of manufacturing, the size of the market, what you can charge, what you need to put in for royalties. I am not familiar with royalty stacking being the deciding factor. The probability of technical success and the size of market are key.” This last remark also implies that the firm had more viable opportunities than it had the resources to pursue. Indeed, complaints about resource constraints as impediments to progress on promising research were more common than complaints about IP. As one research manager from a pharmaceutical firm put it: “What we find limiting in our process is the number of chemists we can bring to bear. That is the most limiting resource we have. We have more targets than we have chemists to work on them.”

---

27One version of this argument is that, if the anticommons problem were widespread but few stopped projects (“empty buildings”) were observed, this could be because of “anticipation and redirection” where firms or university researchers redirect R&D toward projects for which they do not anticipate an anticommons problem. However, to do so with such high success (so that projects did not, in the end, get stopped), decision makers would have to be very prescient about when they would, and when they would not, face such problems. This is unlikely given the uncertainty of early-stage R&D (when researchers do not yet know what tools they might need) and given the lag in patent issuance (so that researchers do not even know which tools are patented—see Marshall, 2000a; Merz et al., 2002). Both of these factors lead to having substantially less than perfect information on potentially blocking patents.

28The manager goes on to say: “Isn’t it great you can identify 200 targets? Yes, but how do you do chemistry on 200 targets? Staffing for a chemical program can run to 12-15 chemists for a serious program. And, despite combinatorial chemistry, at the end of the day more traditional medicinal chemistry is needed to engineer and tailor properties, to build in selectivity, remove interactions. Those generally are the stuff of 10s of compounds to 20s of compounds synthesized with discrete changes to try to target specific things. These are not amenable to high-throughput operations.”
The notion that opportunities often exceed the ability of firms to pursue them suggests that, at least under some circumstances, the social cost of not pursuing projects because of IP considerations may not be as great as one might suppose. Indeed, four of our industry respondents expressed the view that redirection of research effort toward areas less encumbered by patents was not terribly costly for their firm or others because the technological opportunities in molecular biology and related fields were so rich and varied. As one biotech respondent put it, “There are lots of targets, lots of diseases.” Some respondents have suggested that the value of targets has actually declined substantially because companies can’t exploit all of the targets they have, and so firms are more willing to license some of their targets, or abandon some of their patents and let the inventions shift to the public domain, because maintaining large portfolios of low-value patents is expensive.29 On the other hand, one can also argue that even in the presence of rich opportunities, shifting may be costly to the extent that diminishing the number of firms trying to achieve some technical objective makes success less likely.

Evidence of Restricted Access to Upstream Discoveries and Tools

Although biomedical research does not appear to be especially vulnerable to breakdowns over IP negotiations, restricted access to important research tools—especially foundational upstream discoveries—can potentially impede innovation in a field. Moreover, this has occurred in other settings (Merges and Nelson, 1990). Our question is whether the restrictions on access to such upstream discoveries, through, for example, exclusive licensing, has impeded biomedical innovation. As noted above, in contrast to the prospect of an anticommons, this is not a problem of accessing multiple rights but one of accessing relatively few—perhaps even one—patent on a key tool or discovery.

In its report, “Intellectual Property Rights and Research Tools in Molecular Biology,” the NRC (1997) provided a series of case studies on the uses of patents covering a small number of important research tools in molecular biology where the question of restricted access was considered. In the case of the Cohen-Boyer technology for recombinant DNA developed at Stanford University and the University of California—“arguably the defining technique of modern molecular biology” (NRC, 1997, p. 40)—the three patents were broadly licensed on a nonexclusive basis on a sliding scale, providing the basis for the creation of the biotechnology industry as we know it. The license was available for about $10,000

---

29Under plausible conditions, there can also be excessive correlation in research portfolios to the degree that research bandwagons emerge around the mining of what may be considered the most promising veins (Dasgupta and Maskin, 1987). Under such circumstances, a shift to less crowded areas of art would be socially beneficial.
per year plus a royalty of 0.5 to 3 percent of sales (Hamilton, 1997). Stanford and UC eventually had several hundred licensees, and the patent generated an estimated $200 million for the universities.

The second case was that of polymerase chain reaction (PCR) technology, which “allows the specific and rapid amplification of DNA or targeted RNA sequences,” and Taq polymerase, which is the enzyme used in the amplification. The technology was also key to subsequent innovation. It “…had a profound impact on basic research not only because it makes many research tasks more efficient but also because it …made feasible …experimental approaches that were not possible before.” In addition to being a discovery tool, the technology also provides a commercial product in the form of diagnostic tests. Developed by Cetus Corporation, the technology was sold to Roche in 1991 for $300 million. As the NRC (1997) reports, the controversy over the sale of the technology has been primarily over the amount of the licensing fees and the fees charged for the material (Taq polymerase) itself. Although Roche licensed the technology widely, particularly to the research community, they did charge high royalty rates on their licenses for diagnostic service applications. Also, small firms complained about Roche’s fees for applications of the technology outside of diagnostics, which ranged between $100,000 and $500,000 initially with a royalty rate of 15 percent. The high price likely restricted access for some, especially small biotech firms.

The CellPro case, described in detail by Bar-Shalom and Cook-Deegan (2002), also illustrates the potential for the owners of upstream patents to block development of cumulative systems technologies (cf. Merges and Nelson, 1994). Johns Hopkins University’s Curt Civin discovered an antibody (My-10) that selectively binds to an antigen, CD34, found on stem cells but not on more differentiated cells. In 1990, Hopkins was awarded a patent that claims all antibodies that recognize CD34. Baxter obtained an exclusive license. The chief rival was CellPro, a company founded in 1989 based on two key technologies: one a method for using selectively binding antibodies to enrich bone marrow stem cells or deplete tumor cells, and the other an unpatented antibody, 12-8, that also binds to CD34, although in a different class of antibodies from Civin’s My-10 and recognizing a different epitope (binding site) on CD34. CellPro combined these two discoveries with other innovations and know-how to produce a cell separator instrument for use in cancer therapies, particularly bone marrow transplants. Baxter offered CellPro a nonexclusive license for $750,000 plus a 16 percent

30Promega and Roche have been in a long-running dispute over the right to distribute Taq for research uses, with Promega attacking the validity of Roche’s patents. In December 1999, the patent on Taq was ruled unenforceable (for inequitable conduct). Roche appealed the ruling to the Court of Appeals for the Federal Circuit (CAFC). The rest of the case, including Promega’s request for damages and the validity of the PCR patents, will be set aside until after the CAFC rules on the inequitable conduct case. Roche has also faced unfavorable rulings in Europe and Australia.

31The following account draws primarily from Bar-Shalom and Cook-Deegan (2002).
royalty. CellPro felt this was uneconomic and, armed with a letter from outside counsel saying that CellPro’s technology did not infringe and that the patent was probably invalid, decided to move forward with development and to sue to invalidate the patent. Although the jury ruled in CellPro’s favor, the Markman decision reopened the case and the judge ruled for Baxter, assessing treble damages totaling $7.6 million, as well as $8 million in legal fees. The court also ordered license terms similar to (though somewhat higher than) existing licenses, a royalty of over $1,000 per machine. CellPro lost the appeal and went bankrupt. Baxter allowed sales of CellPro’s machine until its own instrument (which Baxter was developing all through this) received FDA approval. In the end, the technology did not prove to be widely effective, and more successful rival technologies were developed by others.

From our perspective, the main lesson of the CellPro case is that, to the degree that upstream patents are broadly interpreted, IP holders can use this broad claim to prevent others from engaging in the subsequent development needed to bring the patented technology to market. This is troubling when the patent owner cannot effectively develop the technology in a timely fashion, which was the case with Baxter, which was at least 2 years behind CellPro in bringing a product to market.

Another case was that of the Harvard OncoMouse, licensed by Harvard exclusively to DuPont. The OncoMouse contained a recombinant activated oncogene sequence that permitted it to be employed both as an important model system for studying cancer and permitting early-stage testing of potential anticancer drugs. After years of negotiations, NIH and DuPont finally signed a memo of understanding in January 2000 that, among other things, permitted relatively unencumbered distribution of the technology from one academic institution to another, although under specific conditions. Although this agreement was the cause of relief on the part of academic researchers, DuPont has just recently begun asserting its patent against selected institutions (Neighbour, 2002). The difficulty is that although the initial press release suggested that these nonpaying rights

---

32Baxter also licensed the patents to two other firms, for $750,000 and 8 percent royalties. These figures illustrate the cost for the license terms for a component of a therapeutic system, with the top of this scale probably at the high end, because CellPro was reluctant to take the terms and Nexell could not profitably produce a product under its terms.

33This provides an example of the scale for legal fees involved in such a case (see below).

34Bar-Shalom and Cook-Deegan (2002) also suggest that royalty stacking may have made the technology economically unfeasible. Hopkins had licensed to B-D, which in turn licensed to Baxter, which in turn licensed to others, with each taking a share of the rents. However, in this case, the license stacking was all on the same technology being passed from hand to hand. Thus this was not a tragedy of the anticommons, but one of a proliferation of middlemen.

to use the OncoMouse covered nonprofit recipients of NIH funding, the actual agreement stated that DuPont would make available similar rights to nonprofit NIH grantees “under separate written agreements.” Because most universities have not asked for those rights, they stand outside of the agreement, and DuPont has begun to approach some of them, claiming that they are infringing Harvard’s patent rights and must take a license from DuPont. The difficulty is that these new license agreements, although also nonpaying in principle, go well beyond the earlier understanding and make a series of stringent demands. Under the proposed agreement, for example, universities cannot use the technology in industry-sponsored research without the sponsor taking a commercial license, *notwithstanding the content or intent of the sponsored research* (Neighbour, 2002). It is unclear at this point, however, what success DuPont will have or how NIH and other institutions will respond.

The most visible recent controversy over access to IP covering a foundational biomedical discovery is the case of embryonic stem cell technology. In brief, Geron funded the research of a University of Wisconsin developmental biologist, James Thompson, who in 1998 first isolated human embryonic stem cells and was issued a very broad patent. The Wisconsin Alumni Research Foundation (WARF), a university affiliate, held the patent and granted Geron exclusive rights to develop the cells into six tissue types that might be used to treat disease as well as options to acquire the exclusive rights to others. Another beneficiary of Geron support, Johns Hopkins University, also provided Geron with exclusive licenses on stem cell technology. In August 2001, WARF sued Geron—who had been trying to expand its rights to include an additional 12 tissue types—to be able to offer licensing rights to Geron’s competitors. In January 2002, a settlement was reached that narrowed Geron’s exclusive commercial rights to the development of only three types of cells—neural, heart, and pancreatic, gave it only nonexclusive rights to develop treatments based on three other cell types—bone, blood, and cartilage, and removed its option to acquire exclusive rights over additional cell types. Geron and WARF also agreed to grant rights free of charge to academic and government scientists to use the stem cell patents for research but not for commercial purposes. Companies wishing to use the stem cells for research purposes would, however, have to license the patents. Thus it would appear that although WARF would like to license the technology broadly,
Geron still retains control over key application areas of the technology and may well decide to pursue those applications itself. Indeed, David Greenwood, CFO and senior VP of Geron, noted that Geron did not have to allow others to develop products in the three areas where it retained exclusive rights. It is unclear, however, whether Geron’s now limited control of IP rights block others’ research on stem cell technology. According to one respondent, infringement of Geron’s IP is commonplace. Moreover, scientific advances in both adult stem cell technology and the use of unfertilized eggs to spawn stem cells may weaken the constraints imposed by Geron’s IP by broadening the access to the commercial development of noninfringing stem cell technology.

We have considered the question of research access to a small number of important upstream discoveries. Evidence from AUTM also suggests that, at least for licensing relationships between universities and small firms, access to relatively upstream discoveries—that is, the kind of discoveries that tend to originate from university labs—is commonly restricted. Specifically, in 1999, 90 percent of licenses to start-ups were exclusive, whereas only 39 percent of licenses to large firms were exclusive (AUTM, 2000). Similarly, in their study of licensing practices for genetic inventions, Henry et al. (2002) report that 68 percent of licenses granted by university and public labs were exclusive, whereas only 27 percent of licenses granted by firms were exclusive. However, only a minority of university-based discoveries are patented to begin with. Henry et al. (2002) [consistent with Mowery et al.’s prior (2001) results] find that only about 15 percent of university-based genetic discoveries are patented, with the vast majority going into the public domain without IP protection.

Even where universities employ restrictive licensing terms, however, it is not clear that such a practice diminishes follow-on discovery, at least when applied to smaller firms. One manager of a university-based start-up suggests that exclusive licensing to smaller biotech firms may actually advance follow-on discovery:

The traditional way universities did this [technology transfer] would be to go license a large company. Those kinds of agreement [include a]…minimal up front [fee] and small royalty, 1-2 percent. What the experience has been then is often the large company will work on it for a while but if it doesn’t look very promising, or they run into problems, which invariably they do…since they haven’t invested much in it, they don’t have a whole lot of motivation to stick with it. So, most of these licensing agreements that universities have done ended

38In response to the question of whether the patents keep others out, a scientist for a stem cell company responded: “No. People are infringing all over the place. None of the stem cell companies have the financial wherewithal to do anything about it. The conventional wisdom is, all these cells seem similar; we will patent and fight later. The first to market will win and then we can fight later. It is not clear who really owns what.” See below for a discussion of infringement of research tools patents in general.
up going nowhere. The idea the university had, and other universities are begin-
ning to do this, is to create small companies like us where the small company has
every motivation to develop it because it is the only intellectual property that
they have. The university then has more control over the situation because they
are an equity owner. Hopefully the small company can develop the molecule to
the point where some real value would be achieved, …where we get somebody
interested, and that somebody will take it over and eventually market it.

Restrictions on the Use of Targets

In our interviews, we heard widespread complaints from universities, bio-
technology firms and pharmaceutical firms over patentholders’ assertion of ex-
clusivity over an important class of research tools, namely “targets,” which refers
to any cell receptor, enzyme, or other protein implicated in a disease, thus repres-
enting a promising locus for drug intervention. Our respondents repeatedly com-
plained about a firm excluding all others from exploiting its target (in the anticip-
ation of doing so itself) or, similarly, a firm or university licensing the target
exclusively. About one-third of respondents (representing all three types of re-
pondents) voiced concerns over patents on gene targets (for example, the COX-
2 enzyme patent, the CCR5 HIV receptor patent, and the hepatitis C protease
patent).

Before considering the degree to which the assertion and licensing of IP on
targets may be restricting their use in downstream research, we should recall that,
to the extent that patents on targets do confer effective exclusivity, even over the
ability of other firms to conduct research on a particular disease, this is the pur-
pose of a patent—to allow temporary exclusivity. Responding to complaints about
restricted access to their patented targets, a respondent from a pharmaceuticals
firm stated: “Your competitors find out that you’ve filed against anything they
might do. They complain, ‘How can we do research?’ I respond, ‘It was not my
intent for you to do research.’” Others also defended their rights to exclude rivals
from their patented targets. More importantly, this right to assert exclusivity may
confer a benefit in the form of increasing the incentives to do the research to
discover the target to begin with, as well as incentives for follow-on investment
to exploit the target. A key question, then, is whether those incentives can be
protected while allowing reasonably broad access.39

Patents on targets, if broad in scope and exploited on an exclusive basis, may
preclude the benefits of different firms with distinctive capabilities and percep-

39A related and important set of questions is how much incentive do patents actually provide (i.e.,
how effective are patents) and is this incentive necessary to bring forth the innovation, given the
alternative means of capturing the rents from the innovation and given public subsidies for inventive
activity (see Scherer, 2002, for a review of these issues).
tions pursuing different approaches to the problem (cf. Nelson, 1961; Cohen and Klepper, 1992). For example, big pharmaceuticals firms have libraries of compounds that might affect the target. These libraries vary by firm and are either kept secret or patented. Thus, narrowing access to the target entails a social cost. The following quote from a large biotech firm summarizes the issue:

The problem is, a target is just that, a target, say, a receptor on a cell. If we did an exclusive license, and we’ve had that opportunity, the only compounds tested would be those in the chemical library of our licensee. Generally there is no chemical relation among the compounds that [act on this target]. The drugs work by occupying the reception site, for example. They [the licensee] throw all the compounds in their library and they may or may not have one that works well. The libraries vary a lot across firms. A lot are patented. Also large pharma companies have huge collections of compounds they’ve synthesized over the last 100 years that have never seen the light of day. With an exclusive license, the odds of finding an active drug, let alone the best, are not good. Therefore, we [the target owner] want the target technology broadly available. Broad licensing only makes economic sense in our view.

The problem of “limited lines of attack” may be greater when exclusive access to a set of targets is held by a smaller firm with limited capabilities, and, as noted above, much of the university licensing of biomedical innovations to small firms is on an exclusive basis. Although perhaps biased, a scientist from a large pharmaceutical firm described the broader capabilities of the large pharmaceutical firm to develop the potential of a target: “[Once the target had been identified], then, the power of the pharmaceutical company comes into play. You put an army of 50 molecular biologists and one-third of the medicinal chemists at [the firm] on this single problem.”

In addition to the constraints imposed by firms’ particular capabilities on the approaches taken to exploiting targets, there are also differences in firm strategies or approaches to drug development. The following quotation from a scientist at a small start-up highlights this problem:

Part of the problem that comes in here is that many of these firms are very specialized and many times somebody holds patents but they don’t do all the

---

40An executive from a large pharmaceutical firm stated: “We all have access to the same body of literature, same collection of issued patents. Same kinds of research people taught in some of the very same universities. But, one person may look at his understanding of a disease and say, ‘I think it’s that this antibody is the problem and if I block that antibody that’s going to cure this disease or treat the disease.’ Someone else may say, ‘It’s not the antibody that’s the problem, it’s the enzyme that synthesizes the antibody,’ or something like that. And take a completely different approach. The chemistries may be similar, may be completely different. Or you may have a compound that has multiple effects and one person may say, ‘I want to focus on this effect of this drug.’ And they’ll start with that as a prototype, but then they’ll start to make to modifications to enhance that effect and minimize the other effects. Let’s take aspirin, for example. Aspirin is a cyclooxygenase inhibitor, it’s an anti-inflamma-
applications feasible. So, what happens is they don’t think about doing something and many times the royalty is so high that other companies, small companies that come up with ideas, may not be able to come in and negotiate the license deal. So, it becomes, by default, what happens now. It’s not that the patent holder says the idea is great but I’m not going to let anybody do it. But, it never occurs to them.

Although limiting access to targets may well limit their exploitation, the question is how often this occurs. We do not have systematic data on the frequency with which this occurs. From interviews and secondary sources, however, we heard of a number of prominent examples of firms’ being accused of asserting exclusivity over (or allowing only limited access to) a target. One case that has garnered a lot of attention is Myriad and its patents on a breast cancer gene (BRCA1). Myriad has been accused of stifling research because it has been unwilling to broadly license diagnostic use of its patents (Blanton, 2002). Myriad counters that over a dozen institutions had been licensed to do tests and that “Myriad’s position is to not require a research license for anybody,” while reserving the right to decide whether particular uses are research or commercial (Bunk, 1999; Blanton, 2002). Myriad sent a letter threatening a lawsuit to the University of Pennsylvania to stop them from performing genetic tests, arguing that this was commercial infringement (see below). Chiron has also developed a reputation for aggressively enforcing its patents on research targets. Chiron has filed suits against four firms that were doing research on drugs that block the hepatitis C virus (HCV) protease (in addition to filing suits against three firms doing diagnostics), and some have claimed that these suits are deterring others from developing HCV drugs (Cohen, 1999). Chiron responded to this claim by pointing out that it had licensed its patent to five pharmaceutical companies for drug development work (as well as at least five firms for diagnostic testing) and that the firms being sued had refused a license on essentially the same terms, which included significant up-front payments as well as “reach-through” royalties on the drug.

Also mentioned by our respondents was the case of telomerase as a potential target for cancer drugs. One university scientist observed: “I’ve asked heads of discovery why they were not using telomerase as a target. The response was, ‘intellectual property.’” A scientist from a biotech firm suggested that Geron, the key IP owner, had been stymied in pursuing this because of the complexity of the
biology\(^{41}\) and had redirected their efforts toward stem cell research, which looked more promising. Upon investigation, we found that Geron had indeed established a substantial patent position, with 56 U.S. patents related to telomerase. However, we also found that there is a great deal of research being done on telomerase in universities (see Figure 1) and that at least three other firms (Amgen, Novartis, Boehringer Ingelheim) are reported to be pursuing telomerase as a target (Marx, 2002b). In addition, Geron presented the results of three separate studies on telomerase-based anticancer projects at the April 2002 meetings of the American Association for Cancer Research. Furthermore, Geron has formed a number of nonexclusive licensing agreements for the exploitation of telomerase, typically with small biotech firms possessing complementary technology. Thus, although

\(^{41}\)Cal Harley of Geron predicted in 1994 that they would be in clinical trials within 4 years. They now hope to have a product in clinical trials in 2003, “if all goes well” (Marx, 2002b).

FIGURE 1 Cumulative citations for “Telomerase” in MEDLINE.
Credit: C. Greider/Johns Hopkins University School of Medicine.
we again see some evidence of researchers being excluded, we do not find a failure to exploit the target.

Others have also complained about being blocked from working on targets because of restrictions imposed by patent holders. For example, *The New York Times* reported, “Peter Ringrose, chief scientific officer at Bristol-Myers, has said there are more than 50 proteins possibly involved in cancer that the company was not working on because the patent holders either would not allow it or were demanding unreasonable royalties” (*The New York Times*, Jan. 8, 2001, p. C2).

Ringrose’s complaint was reported, however, in the context of the announcement of a licensing pact between Bristol-Myers and Athersys, which has a technique for producing proteins without isolating the corresponding gene, allowing use of the protein as a target without infringing patents on the gene, and therefore allowing circumvention of patents on genetic targets. This last point raises a question about the degree to which third-party patents on targets can actually impede firms’ abilities to pursue R&D programs dedicated to particular therapies. We discuss this important issue below in the section on working solutions.

### Costs and Delays

In this section we consider the transactions costs associated with gaining access to one or multiple patents or responding to third-party assertions. For instance, firms may avoid derailing in-house R&D projects but only by engaging in long and costly negotiations or litigation with IP holders. Firms may also invent around or conduct the R&D overseas, possibly at the cost of reducing R&D efficiency. Finally, IP holders may have to invest in monitoring the use of their IP, which, from a social welfare perspective, also constitutes a cost. Over a third of respondents (representing all three sectors) noted that dealing with research tool patents did cause delays and add to the cost of research.

---

42Here we are only concerned with social costs, not the transfers of rents reflected in licensing fees.
43A respondent from a pharmaceutical firm expressed the firm’s frustration:

We do have frustration internally because we can’t do what we consider basic research with a cloned gene, not selling the gene, just using it to make another discovery. To be cut off from that, it sits badly. Because, at the end of the day, you are cut off from tools, from making a breakthrough discovery. Because there is a patent on the human gene, you work with the guinea pig gene, but it is not the best approach. That’s very frustrating. In a number of cases, we can’t work with this protein or this gene and it slows things down. We are looking at ways to get around this. How to not infringe their IP. And, we are coming up with ways to do that, but it involves some labor and time.

Another biotech respondent stated:

If there is a patent on manufacturing in different host cells, and certain others that don’t have a royalty, then, on the last step, you don’t make it in this cell, but over here. But that incurs some technical costs. It is a different system, you are not as familiar with the technology, but you go there because you don’t want to pay the royalty.

University respondents referred to problems of negotiating MTAs (see below).
Litigation costs are likely to be a significant component of the social costs of the assertion and licensing of patents in biomedicine. Furthermore, biomedical patents are more likely to be litigated than are patents on other technologies (Lanjouw and Schankerman, 2001). Although estimates of litigation costs vary, estimates commonly ranged between $1-10 million for each side (see, for example, the discussion of the CellPro case above, where attorney fees were $8 million). One respondent from a biotech firm used the following comparison to put this into perspective:

[XX lawsuit] cost $8 million per year and it was not done in a year. Think about $8 million, about what a biotech could do for $8 million. You could get a lot of science done. Depending on your burn rate, you could easily run a fully dedicated drug discovery program for $8 million. You could have afforded a reasonable number of people to work on that project for that year without any question whatsoever. It wouldn’t surprise me that you could get in that position [because of a suit] that you would have to shut down a particular program.

In addition to these out-of-pocket expenses, we tried to estimate the opportunity cost of engaging in patent litigation. Out of the 16 industry respondents that addressed this issue, all but 1 suggested that litigation imposed a significant burden on the managers and scientists involved. In terms of actual work time, estimates were usually in terms of a few weeks over the course of a year for the individuals involved. Respondents also underscored the time spent worrying about the progress and outcome of the case. One respondent from a biotech described the process:

Going to court is risky any time…. Patentability is complicated. You spend a lot of money educating the jury. You have to go searching through notebooks. If you do decide to sue, you have to be committed. The CEO, CFO are involved. You pull in business people to evaluate. Senior management and the particular inventors spend copious amounts of time on it; it is a huge distraction. They are in deposition, practicing for depositions, researching, respond to interrogatories, providing information. In a year, it costs a couple of man months. The CEO is in deposition for a week. My firm’s experience has been that they want to ask everyone under the sun who was involved. I was tangentially involved and in deposition for a day and half. Duplicating all your files. Each page of your notebook, from 10 years ago, you have to find it, reproduce it. It is an enormous time sink and I think people underestimate it. Clients underestimate it. Even a winner may say, “If I knew then, I might say ‘No’.” Meantime, you are not doing science. Time not spent on new compounds, spent on what will they do in trial tomorrow.

About a third of our respondents addressed the question of negotiation delays or litigation, and nearly all of them felt that the process of sifting through a large number of potentially relevant patents and subsequent negotiations was very time consuming. One characterized the process as “complex, ongoing, and labor intensive,” but a cost of doing business. Another stated: “All these patents makes
research more expensive. It can slow it down, while you secure licenses.” One biotechnology executive suggested that about a third of his firm’s R&D projects suffer delays while licensing and related agreements are worked out. The above-cited quotation on reducing the stack of patents suggests that it commonly took about three or four weeks to sift through the patents potentially relevant to a project, often identifying somewhere between 5 and 20 that may be worth investigating intensively over the course of another three to six months. The respondent noted, however, that the research itself would typically be moving forward during this time. At this point, it would be typically determined that there are about three to six patents where agreements were required, and these negotiations could affect the progress and direction of the firm’s R&D. The costs of negotiations as well as those for reviewing potentially relevant patents can be substantial in absolute terms. One attorney responsible for evaluating research tool IP from a large pharmaceuticals firm provided estimates for the time attorneys were occupied with evaluating the IP of third parties and the time associated with actual negotiations that implied a total of $2 million in annual expenses.

Another respondent from a large pharmaceuticals firm suggested that the transactions costs associated with biotech IP were especially high. He gave the following metric: Lawyers in the small molecule division (of this firm) are responsible for about eight projects each, whereas those in the biotech division can only handle about two projects each, because of the greater complexity of dealing with input technologies in biotech-based projects.

The question is, although perhaps high in absolute terms, do these transactions costs represent a significant expense? The answer depends on the firm. For large pharmaceutical firms, although the expense is by no means trivial, our respondents did not convey that it significantly affected their returns from drug development. For example, one executive responsible for biotech IP gave figures suggesting that the costs for evaluating and negotiating IP rights amounted to about one one-thousandth of the firm’s total R&D budget. This same figure (in absolute terms), however, could represent a significant burden for a small firm, especially one with limited access to capital.

Although our respondents suggest that IP reviews and negotiations are costly and time consuming and that their complexity has increased, it is not clear whether these efforts have increased over the recent past. To address this question, we supplemented our interview data with data from the American Intellectual Property Law Association (AIPLA) and Biotechnology Industry Organization (BIO). The AIPLA’s Report of Economic Survey (AIPLA, 1995; 1997; 2001) reports the number of responding attorneys working in the area of biotechnology and the median percentage of effort dedicated to biotechnology by each respondent. Assuming that the AIPLA’s data are representative (which they may not be, with only a 18-20 percent response rate), they suggest slightly more than a 10 percent increase in the number of attorneys working on biotech between 1995 and 2001 and a 25 percent jump in the amount of time (at least per the median) that each
attorney commonly dedicates to biotechnology. Therefore, there is roughly a 33 percent increase in resources devoted to what one might broadly construed as the “transaction costs” of filing, enforcing and contracting for patents. Ernst & Young LLP’s Annual Biotechnology Industry Reports suggest, however, that in nominal terms, R&D expenditures by biotechnology firms have increased over 80 percent during the 1994-2000 period. If we use an annual R&D cost deflator of 5 percent, then real R&D has increased by about 40 percent. Therefore, attorney activity per R&D dollar is unlikely to have increased significantly in the recent past. Even allowing for some increase in attorneys’ hourly fees, these data suggest that the patenting of research tools has not itself dramatically increased demand for legal resources and, by extension, that the transaction costs have not increased disproportionately.

Universities

There is particular concern among academic commentators about the effects of patenting on university research (Heller and Eisenberg, 1998; Eisenberg, 1999; Barton, 2000; Cook-Deegan and McCormack, 2001). We find only limited support for the idea that negotiations over rights stymie precommercial research conducted in universities. Industrial respondents all claim that university researchers, to the extent they are doing noncommercial work, are largely left alone. In fact, firms often welcome this research because it helps further develop knowledge of the patented technology. University researchers among our respondents confirm this claim. Also, many of the firms interviewed expressed the view that the negative publicity that an aggressive assertion of rights against a university would entail was not worth it. One university technology transfer officer reports that the university will indeed receive letters of notification of infringement. The respondent indicated that the typical response was effectively to ignore such letters and inform the IP holder that the university was engaged in research, did not intend to threaten the firm’s commercial interests, and would not cease its research. Recently, however, this university did agree to engage in negotiations over the use of a research tool over which a firm had rights.

There is a major exception to this norm of leaving university researchers alone, and that is the case of clinical research based on diagnostic tests using

---

44 The American Intellectual Property Law Association (2001) survey, for example, suggests that the charges associated with filing a patent application increased in nominal terms about 25 percent between 1998 and 2000.

45 Recently, however, this university did agree to engage in negotiations over the use of a research tool over which a firm had rights.
Merz, Cho, and their colleagues have recently conducted several studies of the frequency with which clinical labs have been affected by patents on diagnostic tests. One study found that 25 percent of laboratory physicians reported abandoning a clinical test because of patents. They also reported royalty rates ranging from 9 percent for PCR to 75 percent for the human chorionic gonadotropin (hCG) patent. In a follow-up survey of 119 labs capable of performing hemochromatosis testing, they found that many had adopted the test immediately upon publication (Merz et al., 2002). When the patent issued a year later, it was licensed exclusively to SmithKlineBeecham (SKB). Nearly all respondents in the Merz et al. study said they knew of the patent. About half had received letters from SKB. Twenty-six percent said they did not develop the genetic test for hemochromatosis, and another four percent said they abandoned the test, in part because of the patent. Much of the controversy around Myriad’s use of its patent on BRCA1 revolves around this distinction between research and clinical practice. Myriad allows licensees to do tests provided that no fees are charged and the tests are not used for clinical purposes. Myriad also provides reduced fee diagnostics tests ($1,200 vs. $2,680) for NIH-funded projects (Blanton, 2002). However, according to Myriad’s Gregory Critchfield, “If you give test results back to patients, it crosses over the line, and it’s no longer a simple research test. [It] is really a very bright line.” (Blanton, 2002). On the other hand, Merz argues that “There is no clear line to be drawn between clinical testing and research testing, because the state of the art of genetic tests is such that much more clinical study is necessary to validate and extend the early discovery of a disease gene. Thus, the restriction of physicians from performing clinical

46One controversial case was the diagnostic test for the Canavan disease gene mutation. Miami Children’s Hospital held the patent and was charging a royalty of $12.50 per test, even though the doctor did the test himself. Washington University’s Michael Watson was among those complaining that this royalty hurts research and patient care: “We would be happy to pay for some kind of test kit that is faster, better, cheaper. But they are trying to control manual testing, which is not appropriate.” (Regalado, 2000, p. 55). This quotation reflects the opinion of many academics that they should not be forced to pay royalties for “do-it-yourself” technologies. One respondent from a clinical testing company said that the $12.50 royalty for the Canavan test was “substantial” [the cost of the test is reported to be $8 to $9 (Kotulak, 1999)]. Merz et al. (2002) also report royalties of $5 for Gaucher disease and $2 for a cystic fibrosis test, although only for labs doing more than 750 tests per year. Furthermore, they report that license stacking on a battery of tests for Ashkenazi Jewish patients can bring the royalty total to around $100, representing about 20% of the cost.

Another example is the case of the Bogart patent on the triple marker test for Down’s syndrome. Here, the patent owner demanded $5 per test, even though his patented test was only one of three that was needed to accurately determine the presence of Down’s syndrome. While the patent owner pointed out that labs routinely charge $75 for this test, critics noted that the direct costs for the test were also about $5, and that Medicaid reimbursement could be as low as under $10 in some states. This case was all the more controversial because the test was claimed to be widely known before it was patented.
testing will directly reduce the knowledge about these genes."47 One of our respondents, a former medical school dean, echoed these remarks, saying that he had been shown letters of notification of infringement from medical school researchers and that programs had been stopped. He noted that the fact that the universities charge for these tests complicates the matter, but that clinical work is critical for the research process. Cho et al. (2003) report that about half of the diagnostic labs in their sample are also using the test results for clinical research. Cho also notes that sharing of test results within the clinical diagnostic communities is an important means of advancing clinical and scientific understanding of diseases.48

Thus, in some cases, firms are willing to assert their patents against universities that are doing diagnostic testing and charging a fee without licensing the patented tests, and at least some labs are stopping their testing as a result. However, the majority continue with the testing. So long as the university is not generating revenue based on the patented technology, universities appear to be largely left alone, although some firms will send letters.

Materials Transfers

Eisenberg suggests that another significant cost of the patenting of research tools is that associated with the costs and delays in negotiating access to research materials, that is, those associated with materials transfer agreements (MTAs). Although our interviews did not focus on such transactions, to the extent we considered them the interviews also suggested that MTAs are a source of some concern and vexation. An academic researcher reinforced Eisenberg’s findings when he said: “Things are becoming more bureaucratic. MTAs, they are crazy. Before, whenever someone wanted a plasmid from my lab, I would just send it. Now, the university says they own it and I have to go through the IP office. It goes back and forth between the two offices and it takes a long time. Before, we would just send it in the mail, and you would have it and could use it. Basic science is now becoming interested in ‘value.’ The university is particularly interested in value.” Although the material being transferred may or may not be patented, the delays often involve negotiating an allocation of patent rights over the discoveries that may build on the material. Of those who addressed the issue of MTAs nearly all respondents from universities and from industry confirmed that when dealing with MTAs, especially those involving university technology transfer offices, delays could be substantial. For example, one industry respon-

48Personal communication, 1/24/2002.
dent suggested that about a third of the firm’s projects involved some research agreement with a university and that such negotiations result in substantial delays (on the order of months). Some respondents noted that universities are learning and that the process is becoming smoother. NIH has developed a standard MTA for transfers between university or government labs. This MTA, which is endorsed by AUTM, is a single page and does not involve any reach-through claims.

Although materials transfers may indeed be problematic, the relevant question is the extent to which patenting per se has introduced impediments. Experimental biology has long been a competitive field in which scientists were somewhat reluctant to share materials with competing scientists (see Hagstrom, 1974; Sullivan, 1975; Campbell et al., 2002; but see McCain, 1991). Thus it is not clear whether the growing interest in “value” has changed the willingness of scientists to exchange information and materials. Campbell et al. (2002) find that about half of life science faculty report that their requests for materials or information have been denied at least once in the last three years, although 90 percent of requests were granted. About 12 percent of respondents say they have denied requests [Blumenthal et al. (1997) find a very similar result]. Furthermore, although 35 percent report that such withholding is increasing, 65 percent report that has stayed the same or decreased over the last 10 years. Also, although commercial value or industry sponsorship are important predictors of failing to share, the major reason given for not sharing was the effort required to actually produce the material or information, with concerns about scientific competition also being important, and with commercial concerns ranking at the bottom of the list. Blumenthal et al. (1997) have very similar findings, with protecting scientific lead and the expense or scarcity of the materials being the most important reasons for refusing to share materials or information and commercial concerns ranking at the bottom of the list. However, multivariate analyses by Campbell et al. (2002) and Blumenthal et al. (1997) do show that commercial concerns (such as patenting or industry sponsorship) are associated with refusing to share materials and results. These studies did not measure the impact of scientific competition on data sharing.

Walsh and Hong (2002) compare data from surveys of scientists in experimental biology, physics, and mathematics conducted in the 1960s (i.e., before the Bayh-Dole Act and the rise of patenting of academic science) with data from another survey done in 1998 using the same items. They find that secrecy (measured as the willingness to discuss one’s current research with others) has indeed increased overall. Furthermore, secrecy has increased particularly in experimental biology, with only 14 percent of experimental biologists from the recent survey feeling safe to discuss their current work with all others (compared to 45 percent in the 1960s). Although it is difficult to eliminate the expectation of gains from some prospective, patent-based commercialization of some downstream discovery or drug as the cause of this increased secrecy, a multivariate analysis
building on the models used by Campbell et al. (2002) and Blumenthal et al. (1997) shows that the primary predictor of secrecy is scientific competition. Industry-related activity has a mixed effect, with having applied for a patent showing no relation to secrecy, having industry funding related to greater secrecy, and having industry collaborators associated with less secrecy. Thus we have some evidence of an increasing reluctance to be open with scientific findings and materials. However, the results on whether this is due primarily to commercial concerns or to scientific competition are mixed.

What has clearly changed is that, when there is a willingness to share materials, processing that transfer has become more complicated, with the time increasing from days often to months (Eisenberg, 1999). This negotiation can delay the research because the research on the material cannot go forward until the material is transferred. Three university scientists did tell us that they have had to abandon particular projects because of an inability to get materials, but in those cases, they moved on to other projects. However, in each of these cases, the respondent suggested that this was the exceptional case and that for other projects getting research materials was routine. Campbell et al. (2002) find that 21 percent of respondents report abandoning a promising line of research and 24 percent report that their own publications were significantly delayed because of an inability to get access to others’ materials or information. One solution reported by our respondents is that some firms and universities have a standard, take-it-or-leave-it agreement (cf. Eisenberg, 1999). This does reduce delays, but it probably also reduces the number of transactions. Also, several respondents (six from industry and three from universities) suggested that trust that comes from long-term relationships reduces the friction of these kinds of transactions, for example, the willingness to edit the standard agreement to take out offending clauses such as publication review clauses or reach-through rights (Bolton et al., 1994; Uzzi, 1996).

In fact, two of the scientists we interviewed said they routinely send materials without bothering with MTAs, although this would probably upset their technology transfer offices.

In addition, the availability of supply houses to provide licensed copies of patented research materials did facilitate access and distribution according to some

---

49 Although Campbell et al. (2002) do not address MTAs in particular, it is possible that some of the “effort required to actually produce materials or information” (the major reason for not sharing) includes the bureaucratic procedures for dealing with MTAs.

50 In one case, when he finally was able to get the reagent a year later, one respondent decided he did not have time to pursue that line and instead continued to pursue his current research, suggesting that the loss of that avenue of research was not critical.

51 For an extensive discussion of the relation between norms and IP for biotech-related research see Rai (1999).
respondents. Our interviews also point to an intriguing possibility: This commercialization of research materials may actually increase access by creating market-based institutions for distributing them rather than relying on gift exchange among researchers. Several university scientists noted that the demand for important reagents can easily become overwhelming, and licensing it to a commercial firm was seen as a way of increasing, rather than limiting, access for the research community. They also noted that what is sometimes perceived by the requester as reduced access is often the result of a scarcity of materials or time (in addition to scientific competition) preventing compliance, rather than concerns over property rights (see also Campbell et al. 2002 and Blumenthal et al. 1997).

Thus, to the degree that the patenting of biomedical discoveries may impose additional costs and delays in materials transfers, it is largely because Bayh-Dole and related acts have provided university administrations, and especially their technology transfer offices, a vested commercial interest in the disposition of intellectual property.

WORKING SOLUTIONS: OVERCOMING THE ANTICOMMONS AND RESTRICTIONS ON ACCESS

Notwithstanding concerns about the proliferation of IP on research inputs and about the ability of rights holders to limit access to upstream discoveries and promising research targets, the problem was generally considered to be manageable. Firms reported a variety of private strategies and institutional responses that limited the adverse effects of the changing IP landscape. Although negotiations over IP and licensing fees surely affect access, and sometimes choice of projects, our conclusion is that patents on research tools do not yet pose the threat to research projects that they might given the number of patents and diversity of owners. In this section, we review the private strategies adopted by firms and universities and responses from government that allow research and commercialization to go forward despite the proliferation of biomedical intellectual property and claimants over the past decade or so.

One important reason why research tool patents tend not to interfere with research is that it is typically not that difficult to contract. As noted above, although the process of identifying the relevant patents is time consuming, the number of actual patents involved is often moderate, about a dozen or less. Licensing is routine in the drug industry. For example, from 1990 to 1997, there was an average of 379 licenses each year in the drug and chemicals industries (SIC28). For comparison, during this same period there were an average of only 276 li-

---

52 For example, two of our university respondents (in one case asking for material and in the other case being asked) mentioned that the death of a cell line was the explanation for not complying.
licenses per year in electronics (SIC36), where cross-licensing of patents is common (Arora et al., 2001).

Many of our responding firms suggested that if a research tool was critical, they would buy access to it. Several companies that had patents on targets noted that, in addition to trying to develop their own therapeutics, they include the liberal and broad licensing of those targets to others as part of their business model, reflecting a belief on the part of some holders of target patents that by giving several firms a nonexclusive license they increase the chances that one will discover a useful drug. We also observe that most of what might be called “general purpose” tools—tools that cut across numerous therapeutic and research applications that tend to be non-rival-in-use—tend to be licensed broadly. Thus many of the more fundamental (general purpose) research tools, such as genomics databases, DNA chips, recombinant DNA technology, PCR, etc., are made widely available through nonexclusive licenses. Incyte, for example, licensed its genomics database to over 20 pharmaceutical firms (who together account for about 75 percent of total private pharmaceutical R&D). They have also begun expanding their licensing program to include biotech firms and universities as well.53 Similarly, Taq polymerase and thermal cyclers for PCR are available from a variety of authorized reagent and equipment vendors (Beck, 1998). Human Genome Sciences’ semi-exclusive licensing of its databases to only about five firms reflects an exception to this pattern.

Liberal licensing practices are also encouraged to the extent that inventing around tool patents is feasible. Under such circumstances, patent holders are more willing to license on reasonable terms assuming the prospective user does not invent around to begin with. The ability to “invent around” puts an upper limit on the value of the rival’s patent. Indeed, our respondents frequently noted their ability to invent around a patent as one component in their suite of solutions to blocking patents. Firms have also occasionally developed technologies that, it was claimed, made it possible to circumvent a number of the patents in the field.54 Although some respondents argued that target patents were often unassailable, others claimed that for many important diseases (AIDS, many types of cancer, etc.) there are likely to be multiple approaches to the metabolic pathways. One

53Furthermore, Incyte’s license requires users to “grant back” nonexclusive rights to use of genes discovered from its database, providing freedom to operate to firms in the network and creating what Incyte refers to as an “IP Trust.”

54For example, Athersys, a Cleveland-based biotech firm, advertises its RAGE technology, which uses automated techniques to create protein expression libraries (i.e., activate and express every gene and therefore produce every protein) without using any knowledge about the location and structure of the corresponding gene. The company’s website reports that some established pharmaceutical firms (Bristol-Myers Squibb and Pfizer) had licensed this technology (www.athersys.com).
university scientist considered the issue of whether a patent on a target protein could confer exclusive rights to working on a disease:

I have never worked with a disease where one particular protein makes the only difference. A patent gets you exclusive rights to a class of drugs, but there may be other classes…. I could imagine a genetic disease where a single target was involved, but I don’t think that the big medical problems fall into this case. Cancer, AIDS are my areas. AIDS is one hundredth as complex as cancer and even there a single protein is not the solution. Heart disease is as complicated as cancer. Cystic fibrosis is a good example of a single gene, single protein disease.

Thus the specifics of both the patent claims and the scientific understanding determine whether researchers are more or less able to invent around a given patent.

Aside from conventional methods for coming to terms, we find that firms have adopted a set of complementary strategies that create “working solutions” to address either a prospective anticommons (e.g., the need to license numerous tools) or a potentially blocking patent on one tool or discovery. These solutions include (in addition to licensing and inventing around) ignoring patents (sometimes invoking an informal research exemption), going offshore, creating public databases, and challenging patents in court. One pharmaceutical executive summarizes the range of strategies employed:

If someone has a patent on genes, when the gene encodes a therapeutic product and they are ahead of us, we drop those projects. That is different than the case of a gene as a target for a small molecule screen. There we don’t drop the project. If it is just an application, it is not till the patent issues that it is infringing. Lots of these patents are pretty thin. It is an issue whether it is valid. Third, you can do things offshore. Fourth, it may be available for license and fifth, they don’t tend to enforce them.

These working solutions combine to create a free space in the patent landscape that allows research projects to proceed relatively unencumbered.

**Infringement and the “Research Exemption”**

One solution to restrictive patents on upstream inventions is simply to ignore some or all of them. Several respondents noted that infringement of research tool patents is often hard to detect, facilitating such behavior. Thus, if research tool patents have created a minefield, they are mines with fairly insensitive triggers.

University researchers have a reputation for routinely ignoring IP rights in the course of their research (Seide and MacLeod, 1998). Respondents note that many research tools are “do-it-yourself” technologies and therefore they do not feel they should be required to pay royalties for the work. In fact, some strongly believe that these patented technologies were well-known in the scientific community and therefore the patents are not valid (see for example, Kornberg, 1995).
University researchers will often invoke a “research exemption,” although the legal research exemption as construed by the Court of Appeals for the Federal Circuit has been quite narrow.\footnote{Building on Roche Products, Inc. v. Bolar Pharm. Co. (Fed. Cir. 1984) and Embrex v. Service Engineering Corp, the current standard of the Court of Appeals for the Federal Circuit (CAFC) for what qualifies for a research exemption includes uses of patented inventions “for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry.” (Embrex) Although there is some question about whether the term “philosophical inquiry” may actually refer to scientific inquiry (cf. Wegner, 2002), the October 3, 2002 decision of the CAFC in Madey v. Duke, discussed below, corroborates that the CAFC has sustained a narrow interpretation of the research exemption.} Some reagent suppliers facilitate this practice by supplying “unlicensed” (and less expensive) materials, also invoking the research exemption.\footnote{For example, one respondent from a university said that they buy limited quantities of a licensed peptide from a supply house, for $235 per milligram, which they use for benchmarking their experiments. They get the bulk of it, unlicensed, from another lab in the university that can make it for $55 per milligram.} Promega, for example, sells Taq polymerase for about half of what many licensed vendors charge and asserts that many of its customers in university and government labs do not need a license under the experimental use exemption (Beck, 1998).

Many firms claim to be reluctant to enforce their patents against universities to the extent that the university is engaging in noncommercial research, because of the low damage awards and bad publicity that suing a university would entail. For example, William Haseltine of Human Genome Sciences said that they were ready to give academics access to data and reagents related to their patented CCR5 HIV receptor: “We would not block anyone in the academic world from using this for research purposes” (Marshall, 1999). As one university technology transfer officer stated, “Asserting against a university doesn’t make sense. First, there are no damages. You cannot get injunctive relief and/or damages. What have you gained? You’ve just made people mad. Also, these firms are consumers of technology as well. No one will talk to you if you sue. We all scratch each others’ backs. You will become an instant pariah if you sue a university.” Similarly, from the industry side, Leon Rosenberg of Bristol-Myers Squibb said, “Frankly, we all know it is not good form to sue researchers in academic institutions and stifle their progress.” (NRC, 1997, Ch.6, p. 3). These quotations suggest that one limit on opportunism is being a member of a community with the members being able to sanction overly aggressive behavior (Rai, 1999). This vulnerability to such sanctions is based on the need to buy as well as sell technology, or, perhaps especially, to informally trade information. Indeed, there is a strong interest in developing trusting relationships with university researchers to encourage information sharing (for the general issue of trust and information sharing see Uzzi, 1996; for a discussion of the importance for industrial R&D of informal informa-
We rely on lots of outside collaborations with academic labs. Our scientists want to feel on good terms with the academic community. If you start suing, it breaks down the good feeling. We give out our research tools for free, frequently. All we ask is, if you invent anything that is directly related to the tool, you allow us the freedom to practice.

We heard similar comments from those in universities, large pharmaceutical firms, and biotech firms. From the manager of a diagnostics firm, we also heard of a counter-example where a tool owner was not a member of the research community. He described the Canavan case in which the patent holder, Miami Children’s Hospital, was charging $12 per test, which was considered high. When asked why Miami Children’s was behaving differently, he responded:

They are not a company or an organization whose purpose is to continue to do research. They have a product to license, but do not have to sustain relationships. If you license and screw someone, it will get back. This is one time. They hire an obnoxious lawyer who makes people sign nonmarket price deals. What do they have to lose? They are a hospital; patients come to them. They have different interests. They can get away with it. Michigan, or Hopkins, institutions that produce a lot of research, medical schools with a lot in the pipeline, they are looking for licensees, they to want to sustain a relationship. They are very reasonable. They know the business. Canavan is a one-off situation. They don’t have a clue. They are not in the industry. Their lawyer, I will never see him again. Other institutions, we’ll come across each other.

This quotation highlights the repeated game nature of many of these licensing negotiations, which tends to reduce opportunism by the players (as well as noting the problem with one-shot players).

A similar case is DuPont’s recent aggressive assertion of its exclusively licensed OncoMouse patent against universities that did not follow the precise terms of a prior memo of understanding between DuPont and NIH. In commenting on this behavior, Neighbour (2002) mused about why DuPont would do such a thing now that they are out of the business of research in molecular biology. We would suggest that that may be the explanation. They have now ceased to be a part of that community and therefore have little to lose and revenue to gain when they sacrifice the goodwill of that community. Thus DuPont’s behavior is consistent with the notion that a community of practice restrains the aggressive assertion of IP.

Several respondents noted that they actually welcomed universities using their patented technologies because if the university discovers a new use, the patent holder is best positioned to exploit the innovation. If the university becomes a competitor, however, firms feel they then have a right to assert their patents. As noted above, this is particularly evident in cases where university
physicians use patent-protected discoveries as the basis for diagnostic tests (Merz et al., 2002; Blanton, 2002).

As a rule, universities do not assert their rights against one another.57 The following quotation from a professor with over 25 patents summarizes the university researcher’s perspective on whether he had any difficulties in gaining access to research tools from other academics:

It is not a problem. I know this is a murky legal issue, and you should talk to patent lawyers, but in everyday practice, it is not murky. There is a concept of “academic use.” If you have published it, I can use it for academic purposes. I’ve never heard of any case where someone was sued for using patented technologies. I don’t know if it is solidly defensible in the law, but it is the practice. When I have a patented technology, academic colleagues would not even think of paying to use it.

Infringement of research tool patents by firms also appears to be pervasive. A third of the industrial respondents (and all nine university or government lab respondents) acknowledged occasionally using patented research tools without a license, and most respondents suggested that infringement by others is widespread.58 The firms felt that much of their research would not yield commercially valuable discoveries, and thus they saw little need to spend money to secure the rights to use the input technology, particularly because it is very difficult to police such infractions. If the research looked promising, then they would get a license, if necessary.59 Furthermore, at least a few industry respondents argued strongly that using a gene patent as a research tool did not infringe or that infringement was limited to that experiment per se and did not extend to the product discovered

57Some universities feel that they have the moral right to assert against another university, however, if it is commercializing their innovation. One academic stated: “Universities have a general agreement of sharing results freely. There is a research ethic. But if a university were making money off of our technology, then there would be trouble.”

58One respondent stated, “Sometimes we take a license and sometimes we don’t. I think there is a lot of infringement out there. The scientists are not telling their patent counsel.” One respondent was explicit: “If you are confronted with a patent on a target you need, you have to decide what to do. You can infringe, and take the risk of getting sued. They would have to know your practices. If you keep it secret, then they may only find out when you release a product. Then they may know you used it. But the statute of limitations may have run out. Some research tool owners are very aggressive. If they get a hint you are using their tool, they sue. You take all this into account.” Another stated, “I think all the firms in the industry take on some infringement risk, because the behavior in the industry is that you have to try a million things to find one that is promising. Once you identify the promising candidate, then you look into licensing the research tools or sequences you used.”

59If this is true, it suggests that when firms do ask for a license, the patent owner ought to suspect that the tool has been useful in generating a valuable discovery. This knowledge may lead to asking for a high license fee. However, this urge is balanced by the recognition that this promising candidate still needs to get through risky clinical trials, and if the price is too high, the buyer may chose one of his other promising candidates.
(in part) by using the research tool, i.e., that the scope of research tool patent claims is quite limited. In addition, because many of these patents are of debatable validity, they felt that if a license were not available, they could challenge the patent in court. Finally, not only is use of a patented research tool hard to detect, but because of the long drug development process, the 6-year statute of limitations may expire before infringement is detected.

Consistent with this behavior, we also find that firms feel that it is not worth their while to assert their patents on all other firms that might be infringing. They may send a letter, offering terms, but will not aggressively pursue infringers on their marginal patents. Respondents point out that the cost of pursuing these cases greatly outweighs their value in most instances: “The average suit costs millions of dollars. The target is worth $100,000. Even with treble damages, it doesn’t pay to sue.” There is an additional cost, and that is the risk of the patent being invalidated by the court. These firms note, however, that they will aggressively defend a patent central to the firm’s competitive performance. Barring that, with reference to research tool patents, there is a sense that the industry practices “rational forbearance.” (NRC, 1997, Ch. 6).

Respondents also pointed out that patents are national but the research community is global. Thus another means of avoiding research tool patents is to use the patented technology offshore. Although similar to the solution of ignoring the patent, in that it involves using patented technologies without securing the rights, this case differs in that firms are not violating the legal rights of the patent owner, at least not until there a product developed and the firm tries to import the product. Furthermore, a district court decisions in 2001 (Bayer AG v. Housey Pharmaceuticals) suggests that even then the drug maker may not be liable for infringement (see, for example, Maebius and Wegner, 2001).  

In summary, by infringing (and informally invoking a research exemption), inventing around, going offshore, or invalidating patents in court, firms were able to greatly reduce the complexity of the patent landscape. These strategies, combined with licensing when necessary, provide working solutions to the potential problem that an increasingly complex patent landscape represents.

**Institutional Responses by Firms, NIH, USPTO, and Courts**

In addition to these private responses to overcoming the barriers that patents might create, we have also observed firms (especially larger pharmaceutical

---

60Housey Pharmaceuticals had a patent on a method for screening potential drug candidates. Bayer allegedly used this method to discover a drug, but the alleged use was outside the United States. The district court ruled in favor of Bayer on the grounds that the Housey patent did not cover the drug or the method of making the drug, but only a method for finding substances worthy of further development, and that, therefore, Bayer did not infringe by selling the product in the United States. This ruling is an example of a court narrowing the reach of research tool patents (see below). However, it is still not clear how the CAFC will treat this issue (Maebius and Wegner, 2001).
firms), the courts, the NIH and the USPTO to undertake initiatives and policies
that have had the effect (if not always the intent) of broadening and easing access
to research tools. For example, with substantial public, private, and foundation
support, public databases (e.g., GenBank or the Blueprint Worldwide Inc. ven-
ture to create a public “proteomics” database) and quasi-public databases (such as
the Merck Gene Index and the SNPs Consortium) have been created, making
genomic information widely available. Similarly, Merck has sponsored an $8
million program to create 150 patent-free transgenic mice to be made available to
the research community at cost, without patent or use restrictions. According to
our respondents, these efforts partly represent an attempt by large pharmaceutical
firms to undercut the genomics firms’ business model by putting genomic and
other related information into publicly available databases and then competing on
the exploitation of this shared information to develop drug candidates (cf.
Marshall, 1999a; 2001).61 These initiatives represent a partial return to the time
before the genomics revolution, when publicly funded university researchers pro-
duced a body of publicly available knowledge that was then used by pharmaceu-
tical firms to help guide their search for drug candidates.

NIH has also taken the lead in pressing for greater access to research tools.
For example, since 1997, NIH has negotiated with DuPont to provide more favor-
able terms for transgenic mice for NIH and NIH-sponsored researchers (Marshall,
2000b). NIH has also begun a “mouse initiative” to sequence the mouse genome
and create transgenic mice. One of the conditions of funding is that grantees
forgo patenting on this research. NIH also pushed for broader access to stem
cells, as well as for a simplified, one-page MTA without reach-through claims or
publication restrictions. Scientific journals have also pushed for access to research
materials. For example, biology journals have long made it a condition of publi-
cation that authors deposit sequences in public databases such as GenBank or
Protein Data Bank (Walsh and Bayma, 1996). Similarly, when Celera published
its human genome map findings, Science’s editors were able to gain for academic-
large unrestricted access to Celera’s proprietary database.62 Thus large institu-
tional actors have been able to act as advocates for university researchers to
increase their access to necessary research tools.

61For example, the firms in the SNPs Consortium include Bayer, Bristol-Meyers Squibb, Glaxo
Wellcome, Hoechst Marion Roussel, Monsanto, Novartis, Pfizer, Roche, SmithKline Beecham, and
Zeneca. Each firm contributed $3 million, and Wellcome Trust added another $14 million to the
effort. Also, financed by IBM, Canada’s MDS, Inc. and the Canadian government, the Blueprint
Worldwide database could pose a threat to the joint effort of Myriad Genetics, Hitachi, and Oracle to
launch a $185 million effort to map protein interactions, along with for-profit efforts by universities

62Academics have the right to access the data at no charge, do searches and download segments up
to 1 megabase, publish, and patent. They can download the whole database if the university signs an
agreement not to redistribute the data. There are no reach-through provisions or restrictions on publi-
cation. Science also kept a copy of the database in escrow to ensure compliance.
Responding partly to concerns expressed by NIH, universities, and large pharmaceutical firms, the USPTO has also adopted new policies that diminish the prospect of an anticommons. Specifically, in January 2001, the USPTO adopted new utility guidelines that have effectively raised the bar on the patentability of tools, particularly ESTs. These guidelines are designed to reduce the number of “invalid” patents (cf. Barton, 2000).

Some of our respondents have suggested that recent court decisions have also mitigated potential problems due to research tool patents by limiting the scope of tool patents or, in some cases, invalidating them. Thus, although patentholders have the right to sue for infringement, the perception is that they are increasingly likely to lose such a suit. Cockburn et al. (2001) find that the CAFC went from upholding the plaintiff in about 60 percent of the cases to finding for the plaintiff in only 40 percent of the cases in recent years. One case that comes up frequently among our respondents is University of California v. Eli Lilly and Co. As noted above, the University of California tried to argue that its patent on insulin, based on work on rats, covered Lilly’s human-based bioengineered insulin production process. The CAFC ruled that California did not in fact possess this claimed invention at the time of filing; therefore, the claim was not valid, and Lilly was not infringing. Another controversial case was over a transgenic mouse used to study Alzheimer disease. Mayo had been widely distributing the mice at nominal cost to academic researchers. In 1999 Elan Pharmaceuticals sued for infringement and sent subpoenas to individual researchers across the country, demanding their lab notes. In 2000, a District Court judge dismissed the patent infringement suit by Elan Pharmaceuticals against Mayo Foundation, invalidating the patents on the grounds that their claims were covered by an earlier patent. The case of Roche versus Promega over Taq (see above) is another example of the courts ruling against a research tool patent holder. As one respondent put it: “These are good times for a patent infringer and not great times for a patent holder.” This seeming change in the court’s attitude may represent a shift toward more freedom to conduct research without undue concern over research tool patents.

There remains, however, a great deal of uncertainty over how the courts will rule on the validity of research tool patents generally. One case, discussed above, that has been closely watched is the Rochester v. Searle case over COX-2 inhibitors. The critical issue in the case is whether knowledge of a drug target allows one to claim ownership over specific classes of drugs (i.e., how broadly do initial discovery claims extend over future developments building on those discover-

---

63However, they charged some pharmaceutical companies up to $850,000 for a breeding group (Dalton, 2000).

64On August 30, 2002, the CAFC reversed the summary judgment of invalidity based on anticipation and remanded the case back to the District Court for further proceedings. The District Court and the CAFC have not yet ruled on the breadth of the Elan patent claims.
ies). Although the district court recently dismissed Rochester’s complaint of infringement (see footnote 16), the case will apparently be appealed, and the ultimate outcome may have important implications for how patents on key upstream discoveries affect subsequent drug development and commercialization.

**DISCUSSION AND CONCLUSION**

In this chapter, we have considered two possible impacts of the patenting of research tools on biomedical research. First, we considered whether the existence of multiple research tool patents associated with a new product or process poses particular challenges for either research on or commercialization of biomedical innovations. Second, we examined whether restricted access to some upstream discovery—perhaps protected by only one patent—has significantly impeded subsequent innovation in the field. In brief, we find that the former issue—the “anticommons”—has not been especially problematic. The latter issue of access, at least to foundational upstream discoveries, has not yet impeded biomedical innovation significantly, but our interviews and prior cases suggest that the prospect exists and ongoing scrutiny is warranted.

The patenting of research tools has made the patent landscape more complex. As suggested by Heller and Eisenberg (1998), our interviews confirm that there are on average more patents and more patentholders than before involved in a given commercializable innovation in biomedicine, and many of these patents are on research tools. Despite this increased complexity, almost none of our respondents reported commercially or scientifically promising projects being stopped because of issues of access to IP rights to research tools. Moreover, although we do not have comparably systematic evidence on projects never undertaken, our interviews suggest that IP on research tools, although sometimes impeding marginal projects, rarely precludes the pursuit of more promising projects. Why? Industrial and university researchers have been able to develop “working solutions” that allow their research to proceed. These working solutions combine taking licenses (i.e., successful contracting), inventing around patents, going offshore, the development and use of public databases and research tools, court challenges and using the technology without a license (i.e., infringement), sometimes under an informal and typically self-proclaimed research exemption. In addition, the members of a research community (which includes both academic and commercial researchers) are somewhat reluctant to assert their IP against one another if that means they will sacrifice the goodwill and information sharing that comes with membership in the community. Changes in the institutional environment, particularly new USPTO guidelines and some shift in the courts’ views toward research tool patents, as well as pressure from powerful actors such as NIH (stimulated perhaps by the early concerns articulating the anticommons problem) also appear to have further reduced the threat of breakdown. Finally, the very high technological opportunity in this industry means that firms can shift their re-
search to areas less encumbered by intellectual property claims, and, therefore, the walling off of particular areas of research may not, under some circumstances, exact a high toll on social welfare.

Although stopped and stillborn projects are not evident, many of the working solutions to the IP complexity can impose social costs. Firms’ circumvention of patents, the use of substitute research tools, inventing around or going offshore—although all privately rational strategies—constitute a social waste. Court challenges and even the contract negotiations themselves can also impose significant social costs. Litigation can be expensive and non-out-of-pocket costs, represented by the efforts devoted to the matter by researchers and management, can be substantial. Even when there is no court challenge, the negotiations can be long and complex and may impose costly delays. Disagreements can and have led to litigation, which is especially costly for small firms and universities. It is difficult to know, however, how much contracting costs in biomedicine reflect an enduring feature of IP in biomedicine and how much is transitional, arising from the uncertainty associated with the newness of the technology and uncertainties about the scope and validity of patent claims. Moreover, as new institutions (i.e., universities) and firms become owners of intellectual property, there is a costly period of adjustment as these new actors learn how to manage their IP effectively. The development of standard contracts and templates may be helpful in diminishing these adjustment costs, and funding agencies such as NIH can play an important role in developing and encouraging the use of such standards.

The second issue that we examined is the impact on biomedical innovation of restricted access to research tools. In thinking about the issue of access, it is helpful to distinguish research tools along two dimensions. First, it is obviously of interest how essential or “foundational” a research tool is for subsequent innovation, both in the sense of whether the tool is key to subsequent research and in the sense of the breadth of innovation that might depend upon its use. Is the research tool a key building block for follow-on research on a specific approach to a specific disease, is the tool key to advance in a broad therapeutic area, or might its application even cut across a range of therapeutic and diagnostic domains?

A second dimension of interest is the degree to which a research tool is rival-in-use. By “rival-in-use” we mean research tools that are primarily used to develop innovations that will compete with one another in the marketplace. For instance, in the case of a receptor that is specific to a particular therapeutic approach to a disease, if one firm finds a compound that blocks the receptor, it undermines the ability of another to profit from its compound that blocks the same receptor. The defining feature of research tools that are not rival-in-use is that the use of the research tool by one firm will not typically reduce others’ profits from using it. Such tools include PCR, microarrays, cre-lox, and combinatorial libraries. From a social welfare perspective, a research tool that is not rival-in-use is like a public good in that it has a high fixed cost of development and zero
or very low marginal cost in serving an additional user. Thus maximization of
social welfare requires that the tool be made available to as large a set of users as
possible.

We have observed that holders of IP on nonrival research tools often charge
prices that permit broad access, at least among firms. In some of these cases, the
IP holders have also charged higher prices to commercial clients and lower prices
to university and other researchers who intended to use the tool largely for non-
commercial purposes. From a social welfare perspective, such price discrimina-
tion expands the use of the tool and is indeed welfare enhancing. There are, how-
ever, cases in which the IP holder cannot or does not develop a pricing strategy
that allows low-value and academic projects access to the tool, as for instance in
the case of DuPont’s initial terms for the cre-lox technology or Affymetrix’s
initial terms for GeneChips. However, DuPont eventually bowed to pressure from
NIH (although, as noted above, the issue is not entirely settled) and Affymetrix
developed a university pricing system that greatly increased access (while others
developed do-it-yourself microarrays).65

The concern with regard to IP access tends to be the greatest when a research
tool is rival-in-use and is potentially key to progress in one or more broad thera-
pytic areas. When a foundational research tool is rival-in-use, the IP holders
often either attempt to develop the technology themselves or grant exclusive li-
censes. As suggested above, exclusive exploitation of a foundational discovery is
unlikely to realize the full potential for building on that discovery because no one
firm can even conceive of all the different ways that the discovery might be ex-
ploded, let alone actually do so. Geron’s exclusive license for human embryonic
stem cell technology shows how restrictions on access to an important, broadly
useful rival-use technology can potentially retard its development.66 A more pro-
saic example is the pricing of licenses for diagnostic tests. Myriad’s (and others’)
licensing practices show that, to the degree that a high price on a diagnostic test
puts it out of the reach of clinics and hospitals involved in research that requires
the test results, clinical research may be impeded, yielding long-term social
costs.67 The social welfare analysis of this situation is, however, not straightfor-

---

65We conjecture that it is exactly these non-rival-in-use technologies with many low-value uses that
are likely to benefit from NIH intervention, if necessary, because there will be a large constituency of
users who want access (including many researchers at NIH itself), most of the research community
uses will be low value, and the cost to the patent owner of allowing these nonrival uses is low, because
the high-value uses are not necessarily affected.

66Of course, President Bush’s decision to deny federal funding to human embryonic cells lines
created after August 9, 2001 limited the ability of researchers to invent around Geron’s patents
(Kotulak and Gorner, 2001).

67Here the difficulty is associated with the fact that the same activity that is rival-in-use (providing
commercial diagnostic services) is also the (possibly non-rival-in-use) research use. The difficulty of
separating these two activities in the American system of funding clinical research contributes to the
problems associated with patents on diagnostic uses of genes.
ward. Even though knowledge, once developed, can be shared at little additional
cost and may be best exploited through broad access, it does not follow that social 
welfare is maximized by mandating low-cost access if such access dampens the 
incentive to develop the research tool to begin with.

Many of the same kinds of “working solutions” that mitigate the prospect of 
an anticommons also apply to the issue of access for research. Our interviews 
suggest that a key “working solution,” however, is likely infringement under the 
guise of a “research exemption.” Firms and universities frequently ignore exist-
ing research tool patents, invoking a “research exemption” that is broader than 
the existing legal exemption and that is supported by norms of trust and exchange 
in the research community. As discussed above, such instances of possible 
fringement, especially on the part of universities, are tolerated by IP-holding 
firms, both for normative reasons and because of the high cost of enforcing rights 
through litigation, relative to the low payoff for stopping a low-value infringe-
ment. One can rationalize the failure of the IP holder to aggressively monitor 
intrinsement as a form of price discrimination, and, as suggested above, eco-
nomic theory suggests that such price discrimination can improve social wel-
fare.68

There are two central questions to ask when considering the effects of a 
given research tool patent on the progress of biomedical research. The first has to 
do with the specifics of the biology in question: Does current scientific knowl-
edge provide us with many or few opportunities for modifying the biological 
system in question? As science progresses, we are likely to see an oscillation, 
with new discoveries opening promising but narrow shortcuts and further explo-
ration of those discoveries uncovering a variety of lines of attack on the problem. 
Where there are many opportunities, the likelihood of a research tool patent im-
peding research is smaller. Here again, the Geron case provides an illustration, 
with the recent development of alternatives to the use of embryonic cells for 
exploiting the promise of stem cells mitigating the restrictive impact of Geron’s 
control over embryonic stem cell technology.

The second question has to do with specifics of the legal rights in question, 
and was highlighted by Merges and Nelson (1990) and Scotchmer (1991): Does 
the scope of claims in this patent cover few or many of the research activities 
using this technology? As the USPTO and the courts become more familiar with 
the technology, uncertainty over the scope of patent claims should diminish. The 
eventual outcome of the Rochester v. Searle/Pharmacia COX-2 case, for example, 
is likely to have significance beyond the parties’ considerable financial stakes. If 
the district court decision is upheld, we are likely to see research proceed with 
reduced concern over upstream research tool patents, although one should then

---

68 As long as the infringing uses do not reduce the value of the tool to the users with a high willing-
ness to pay, such price discrimination is likely to be privately profitable as well.
consider the impact of that decision on the incentives for developing that class of upstream discovery.

Through a combination of luck and appropriate institutional response, we appear to have avoided situations where a single firm or organization using its patents has blocked research in one or more broad therapeutic areas. However, the danger remains that progress in a broad research area could be significantly impeded by a patentholder trying to reserve the area exclusively for itself. The question is whether something systematic needs to be done. One possibility that has been considered is a revision of the law providing for research exemptions to better reflect the current norms and practices of the biomedical research community (cf. Rai, 1999; Ducor, 1997, 1999). One difficulty is that it is not easy to discern when research is commercial or noncommercial notwithstanding what kind of institution is doing the research (cf. OECD, 2002). Thus it is not apparent that society would benefit from a policy response as opposed to continued reliance on current ad hoc practices of de facto infringement under the informal rubric of the “research exemption.” The viability of this latter approach may, however, be undermined by the recent October, 2002 CAFC decision in Madey v. Duke which effectively narrows the research exemption to exclude, in essence, any use of IP in the course of university research. The effect of this decision is not to make the unauthorized use of others’ IP in academic biomedical research illegal; such uses, as suggested above, were already likely illegal in light of recent, pre-Madey interpretations of the research exemption. Rather, this decision will focus attention on such practices, sensitizing both faculty and university administrations to the possible illegality of—and liability for—such uses of IP. This could well chill some of the “offending” biomedical research that is conducted in university settings. Given the importance of this informal exemption for allowing open science to proceed relatively unencumbered, this outcome would be unfortunate. Thus, policymakers should ensure an appropriate exemption for research intended for the public domain.

We cannot, therefore, rule out future problems resulting from patents currently under review, court decisions, new shifts in technology, or even assertions of patents on foundational discoveries. Therefore, we anticipate a continuing need for the active defense of open science. Yet the social system we observe has appeared to develop a robust combination of working solutions for dealing with these problems. Recent history suggests that these solutions can take time and expense to work out, and the results may not be optimal from either a private or social welfare perspective, but research generally moves forward. It should also be recalled that patents benefit biomedical innovation broadly by providing incentives that have called forth enormous investment in R&D (cf. Arora et al., 2002), and that the research tools developed have increased the productivity of biomedical research (e.g., Henderson et al., 1999).

Thus, our conclusion is that the biomedical enterprise seems to be succeeding, albeit with some difficulties, in developing an accommodation that incorpo-
rates both the need to provide strong incentives to conduct research and development and the need to maintain free space for discovery. As technologies change and as court decisions such as Madey v. Duke emerge, these issues may need to be periodically revisited.

REFERENCES


Neighbour, A. (2002). “Presentation to the National Cancer Policy Board,” Institute of Medicine, April 23.


